Comorbidity, outcome and treatment of DSM-IV major depressive disorder in psychiatric care by Melartin, Tarja
Department of Mental Health and Alcohol Research,
National Public Health Institute,
Helsinki, Finland
and
Department of Psychiatry, University of Helsinki, Finland
COMORBIDITY, OUTCOME AND
TREATMENT OF DSM-IV MAJOR DEPRESSIVE
DISORDER IN PSYCHIATRIC CARE
Tarja Melartin
Academic Dissertation
To be publicly discussed, with the permission of the Medical Faculty of the University of
Helsinki, in the auditorium of the Department of Psychiatry in Helsinki, Lapinlahdenkatu 1,
on January 21, 2005, at 12 noon.
Publications of the National Public Health Institute
Copyright National Public Health Institute
Julkaisija-Utgivare-Publisher    
Kansanterveyslaitos (KTL)
Mannerheimintie 166
FIN-00300 Helsinki, Finland
puh. (09) 4744 1, fax (09) 4744 08
Folkhälsoinstitutet
Mannerheimvägen 166
FIN-00300 Helsingfors, Finland
tel. (09) 4744 1, fax (09) 4744 08
National Public Health Instutute (NPHI)
Mannerheimintie 166
FIN-00300 Helsinki, Finland
tel. +358-9-4744 1, fax +358-9-4744 08
ISBN 951-740-480-8
ISBN 951-740-481-6 (pdf)
ISSN 0359-3584
ISSN 1458-6290 (pdf)
Yliopistopaino, Helsinki 2004
Supervisor:
Professor Erkki Isometsä, M.D., Ph.D.
Department of Psychiatry, University of Helsinki, Finland
Department of Mental Health and Alcohol Research,
National Public Health Institute, Helsinki, Finland
Reviewers:
Acting Professor, Docent Jukka Hintikka, M.D., Ph.D.
Department of Psychiatry, University of Kuopio, Finland
and
Docent Jyrki Korkeila, M.D., Ph.D.
Department of Psychiatry, University of Turku, Finland
Opponent:
Professor Heimo Viinamäki, M.D., Ph.D.
Department of Psychiatry, University of Kuopio, Finland

"...sillä minä olen itse metsä, kulku metsän läpi, askel joka miettii, miettii eikä saavu koskaan
perille, puiden järkytys ja villiaasin laukka läpi lehtojen,
minä olen itse pako ja kohtaaminen, pako ja kohtaaminen, hitaat vaunut ja särkynyt pyörä, melu
pyörän sektorissa, toisessa sektorissa hiljaisuus,
olen äänetön ajuri ja outo vieras, joka astuu peilin sisältä ja hämmästyy,
en tiedä kuka olen, sillä kun käsitän itseni olen jo toinen, olen moni, olen yksin ja matkalla
kaukaiseen vihertävään tähteen jonka kirjon olen vanginnut tähän,...
...olemme matkalla, yhä vain matkalla puheen vaunuissa; puhe tulee menneisyydestä ja leviää
peruuttamattomien sanojen alati sykkiväksi kehäksi,
äänessäsi on pilviä, sade virtaa puiden latvoista, kuljen läpi lehtien, sateiden, tulee yö, toiset
avaruudet kajastavat,
minä yhä kuljen, pitkän talvisen matkan."
Yö tulee varhain.
Kohta on talvi
kuin kaivo, syvä ja kylmä.
                                   Eeva-Liisa Manner
                                   Hevonen minun veljeni, Hevosrunot 1956-1976;
                                   katkelmat runoista Hukattu motiivi ja
                                   Syksyn tulon kuvaus
To Lauri, Siiri, and Heta

CONTENTS   
 TIIVISTELMÄ                                                                                                                     9
 ABBREVIATIONS                                                                                                                  11
 1.  ABSTRACT                                                                                                                   13
 2.  LIST OF ORIGINAL PUBLICATIONS                                                                                             15
 3.  INTRODUCTION                                                                                                               16
 4.  REVIEW OF THE LITERATURE                                                                                                  18
       4.1  Diagnosis of major depressive disorder (MDD)                                                                        18
              4.1.1  Melancholic features of MDD                                                                               19
              4.1.2  Atypical features of MDD                                                                                   20
       4.2  Prevalence of MDD in general populations                                                                           20
       4.3  Aetiology of MDD                                                                                                    21
              4.3.1  Multifactorial model                                                                                       21
              4.3.2  Heritability and genetic risk factors                                                                      22
              4.3.3  Structural, functional and neurochemical findings                                                          22
       4.4  Comorbidity of MDD                                                                                                  23
              4.4.1  Definition of the concept                                                                                  23
              4.4.2  Comorbidity of MDD in general populations                                                                  24
              4.4.3  Comorbidity of MDD in clinical samples                                                                    24
       4.5  Course and outcome of MDE                                                                                          25
              4.5.1  Methodological aspects in defining outcome                                                                25
              4.5.2  Duration of MDE in general populations                                                                    26
              4.5.3  Outcome of MDD                                                                                             26
                        4.5.3.1  Clinical factors as predictors of outcome                                                     27
                        4.5.3.2  Comorbidity as a predictor of outcome in clinical studies                                     28
                        4.5.3.3  Psychosocial factors as predictors of outcome                                                 29
                        4.5.3.4  Melancholic subtype as predictor of outcome and stability
                                      of melancholic features                                                                   29
                        4.5.3.5  Atypical and psychotic subtypes as predictors of outcome                                      30
       4.6  Treatment of MDD                                                                                                    30
              4.6.1  Antidepressant treatment                                                                                   30
              4.6.2  Psychosocial treatment                                                                                     31
              4.6.3  Combination treatment                                                                                      31
              4.6.4  Treatment adherence                                                                                        31
              4.6.5  Studies on treatment adequacy and adherence                                                               32
 5.  AIMS OF THE STUDY                                                                                                         36
 6.  METHODS                                                                                                                    37
       6.1  General study design                                                                                                37
       6.2  Screening                                                                                                           37
       6.3  Baseline evaluation                                                                                                 39
              6.3.1  Diagnostic measures                                                                                        39
              6.3.2  Exclusion criteria                                                                                         39
              6.3.3  Observer and self-report scales                                                                            39
              6.3.4  Melancholic subtype and neuroticism                                                                       40
              6.3.5  Patients’ attitudes towards treatments                                                                    40
       6.4  Follow-up procedure                                                                                                 40
              6.4.1  Study drop-outs                                                                                            41
              6.4.2  Outcome measures                                                                                           41
                   6.4.2.1  Life-chart methodology                                                                              41
              6.4.3  Definitions for duration of the index episode                                                             42
       6.5  Treatments provided and their continuity                                                                            42
              6.5.1  Self-reported reasons for discontinuity                                                                    42
              6.5.2  Self-reported treatment adherence                                                                          43
       6.6  Data analyses                                                                                                       43
 7.  RESULTS                                                                                                                    44
       7.1  Current comorbidity of psychiatric disorders in MDD (Study I)                                                     44
              7.1.1  Clinical and demographic characteristic of the sample                                                     44
              7.1.2  Current overall comorbidity                                                                                44
              7.1.3  Variations of comorbidity by sociodemographic and clinical factors                                    44
                        7.1.3.1  Axis I and axis II                                                                             44
                        7.1.3.2  Gender, age, marital status and residential area                                              45
                        7.1.3.3  Inpatient and outpatient status                                                                48
                        7.1.3.4  Lifetime depressive episodes                                                                   48
                        7.1.3.5  Melancholic features (Study III)                                                               48
       7.2  Outcome of MDD (Study II)                                                                                          49
              7.2.1  Duration of the index episode                                                                              49
              7.2.2  Predictors of duration of the index episode                                                               49
              7.2.3  Relapses and recurrences                                                                                   51
       7.3  Stability and course of melancholic features (Study III)                                                           53
              7.3.1  Course of melancholic MDD                                                                                  53
              7.3.2  Stability of melancholic features                                                                         53
       7.4  Antidepressant and psychosocial treatments (Study IV)                                                              54
              7.4.1  Antidepressants                                                                                            54
                        7.4.1.1  Antidepressants received in the acute phase                                                    54
                        7.4.1.2  Continuity of treatment                                                                        54
                        7.4.1.3  Predictors of premature termination                                                           54
                        7.4.1.4  Consequences of premature termination                                                         56
                        7.4.1.5  Self-reported reasons for terminating antidepressants                                          56
                        7.4.1.6  Self-reported antidepressant adherence                                                        58
              7.4.2  Psychosocial treatments                                                                                    58
                        7.4.2.1  Treatments received in the acute phase                                                        58
                        7.4.2.2  Continuity of psychosocial treatments                                                         58
                        7.4.2.3  Self-reported psychosocial treatment adherence                                                59
              7.4.3  Attitudes towards treatments                                                                               59
 8.  DISCUSSION                                                                                                                 60
       8.1  Main findings                                                                                                       60
       8.2  Methods                                                                                                             61
              8.2.1  Representativeness of the cohort sample                                                                    61
              8.2.2  Study refusals and drop-outs                                                                               61
              8.2.3  Diagnostic measures                                                                                        62
              8.2.4  Life-chart and definitions for outcome                                                                    62
       8.3  Current comorbidity of psychiatric disorders in MDD (Study I)                                                     63
       8.4  Outcome of MDD (Study II)                                                                                          64
       8.5  Stability and course of melancholic features (Study III)                                                           66
       8.6  Antidepressant and psychosocial treatment in MDD (Study IV)                                                     68
 9.  CONCLUSIONS AND FUTURE IMPLICATIONS                                                                                70
       9.1  Conclusions                                                                                                         70
       9.2  Clinical implications                                                                                               71
       9.3  Implications for future research                                                                                    72
10.  ACKNOWLEDGEMENTS                                                                                                           73
11.  REFERENCES                                                                                                                 76
9TIIVISTELMÄ
Tämä tutkimus on osa Kansanterveyslaitoksen ja Helsingin ja Uudenmaan sairaanhoitopiirin
Peijaksen sairaalan psykiatrian tulosyksikön vakavan masennustilan etenevää seurantatutki-
musta (Vantaa Depression Study),  jossa seurataan 269 ajankohtaisesta (DSM-IV) vakavasta
masennustilasta kärsivää psykiatrisen erikoissairaanhoidon avohoito- ja sairaalapotilasta.
Kaiken  kaikkiaan  Peijaksen  psykiatrisessa  erikoissairaanhoidossa depressiivisten oireiden
osalta  seulottiin 806,  ja  haastateltiin  puolistrukturoidulla  haastattelumenetelmällä (WHO
Schedule  for Clinical Assessment in Neuropsychiatry [SCAN], Version 2.0) 542 aikuispoti-
lasta  (20-59v.).  Tutkimukseen valikoituneet (N=269) täyttivät  ajankohtaisen vakavan ma-
sennustilan oirekriteerit, ja heidät  haastateltiin  puolistrukturoiduin  haastattelumenetelmin
myös kaikkien  muiden  psykiatristen  häiriöiden diagnosoimiseksi. Poissulkukriteerit olivat
DSM-IV  bipolaarihäiriö  I ja  II,  skitsoaffektiivinen häiriö,  skitsofrenia ja  muut psykoosit,
sekä orgaaninen tai kemiallisen aineen aiheuttama mielialahäiriö.
Sisäänottovaiheen jälkeen 6 ja 18 kk:n seurannoissa vakavan masennuksen ja muiden sama-
naikaisten häiriöiden oireet kartoitettiin haastattelemalla potilaat uudelleen puolistrukturoi-
duin diagnosointihaastattelumenetelmin. Tämän lisäksi ajankohtaisen sekä toistuvien/uusiu-
tuvien depressioepisodien ajallinen kesto koottiin yksityiskohtaiseksi graafiseksi kuvaajaksi
(lifechart), jossa seuranta-aika on jaettu DSM-IV kriteereiden mukaan kolmea eri toipumis-
tasoa kuvaavaan jaksoon:   1) täydellinen toipuminen (0/9 oiretta),  2) osittainen toipuminen
(1-4/9 oiretta) ja  3) ei toipunut (5+/9 oiretta).  Hoitokäynti- ja oirestatustietojen lisäksi kar-
toitettiin seuranta-ajan elämäntapahtumat, joiden avulla pyrittiin myös lisäämään ajoituksen
tarkkuutta.
Tutkimuksessa  todettiin  tyypillisen  psykiatrisen  erikoissairaanhoidon  masennuspotilaan
kärsivän monista samanaikaisista ajankohtaisista häiriöistä. Yli puolella diagnosoitiin sama-
naikainen ahdistuneisuushäiriö (57%), vajaalla puolella persoonallisuushäiriö (44%), ja nel-
jänneksellä alkoholiriippuvuus tai alkoholin väärinkäyttö (25%). Ainoastaan viidenneksellä
(21%) potilaista oli yksinomaan vakava masennustila.
Vakavasta masennustilasta täydelliseen toipumisen todettiin vievän keskimäärin kahdeksan
kuukautta, joten huolimatta uusista hoitomenetelmistä ennuste ei tässä suhteessa ole paran-
tunut. Potilaat tosin reagoivat hoitoon suhteellisen nopeasti, noin 4-8 viikossa, mutta ongel-
maksi  muodostui  pitkäkestoinen  osittaisen toipumisen tila,  jossa toimintakyky usein oli
edelleen alentunut ja depressiivinen oireilu jatkui, vaikkakin lievempänä. Lisäksi noin 40%
potilaista masentui vakavasti uudelleen puolentoista vuoden seurannan aikana. Uusiutuvien
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episodien kesto oli kuitenkin lyhyempi,  ja  ne  olivat lievempiä kuin ensimmäinen, hoitoon
tuonut sairausjakso.  Toipumisaikaa ennustivat useat tekijät,  merkittävimmin masennuksen
syvyys ja ajankohtainen monihäiriöisyys.  Oiresyvyys  oli myös voimakas uusiutumista en-
nustava tekijä. Monihäiriöisyys tai masennuksen ennustetekijät eivät eronneet merkittävästi
vakavan masennustilan melankolisessa ja ei melankolisessa alatyypissä. Melankoliset piir-
teet eivät myöskään seurantaepisodeissa olleet kovin pysyviä.
Psykiatrisessa  erikoissairaanhoidossa  akuutin vaiheen alussa lääkehoitoa sai 88% ja psyko-
sosiaalista  tukea 98%  masennuspotilaista,  ja  useimmat suhtautuivat hoitoon myönteisesti.
Tästä  huolimatta  antidepressiivinen lääkehoito  keskeytyi  liian aikaisin noin puolella poti-
laista, usein potilaan omasta päätöksestä. Kokonaan ilman hoitokontaktia seurannan lopussa
oli noin kolmannes niistä potilaista,  jotka  eivät saavuttaneet täydellistä toipumista. Negatii-
vinen hoitoasenne kohdistui  useammin  lääkitykseen kuin psykososiaaliseen tukeen, ja vai-
kutti ennustavan hoidon liian  aikaista keskeytymistä. Voidaankin tiivistäen todeta, että suu-
rin haaste nykyisessä psykiatrisessa  erikoissairaanhoidossa on hoidon asianmukaisen jatku-
vuuden turvaaminen.  Ilman  jatkuvuutta  masennuksen Käypä hoito-suositusten mukainen
hoito ei voi toteutua. Tässä tehtävässä perusterveydenhuollon ja erikoissairaanhoidon yhtei-
nen vastuunkantaminen ja yhteistyö on välttämätöntä, ja toimivien alueellisten hoitoketjujen
luominen yhteisine tavoitteineen vääjäämätön haaste.
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ABBREVIATIONS
APA             American Psychiatric Association
BAI             Beck Anxiety Inventory
BDI             Beck Depression Inventory
CI              Confidence Interval
CIDI            Composite International Diagnostic Interview
CRF             Corticotrophin releasing factor
DIS             Diagnostic Interview Schedule
DSM             Diagnostic and Statistical Manual of Mental Disorders
DSM-III         Diagnostic and Statistical Manual of Mental Disorders, 3rd edition
DSM-III-R       Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised
DSM-IV          Diagnostic and Statistical Manual of Mental Disorders, fourth edition
ECA             Epidemiological Catchment Area Study
ECT             Electroconvulsive therapy
EPI             Eysenck Personality Inventory
GHS-MHS         Mental Health Supplement of German National Health Interview and
                Examination Survey
HAM-D           Hamilton Rating Scale for Depression
HPA             Hypothalamic-pituitary-adrenal
HS              Beck Hopelessness Scale
HUCS            Helsinki University Central Hospital
ICD             International Classification of Diseases
ICD-10          International Classification of Diseases, 10th edition
IMSR            Interview Measure of Social Relationships
IRLE            Interview for Recent Life Events
LIFE            Longitudinal Interval Follow-up Evaluation
LR              Logistic regression
MAOI            Monoamine oxidase inhibitor
MDD             Major depressive disorder
MDE             Major depressive episode
NaSSA           Noradrenergic and specific serotonergic antidepressant
NCS             National Comorbidity Survey
NCS-R           National Comorbidity Survey Replication
NIMH            National Institute of Mental Health
NOS             Not otherwise specified
NS              Non significant
CDS             Collaborative Depression Study
OR              Odds Ratio
PD              Personality disorder
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PMCD            Peijas Medical Care District
PSSS-R          Perceived Social Support Scale - Revised
RDC             Research Diagnostic Criteria
RIMA            Reversible inhibitors of monoamine oxidase
SAS-SR          Social Adjustment Scale-Self Report
SCAN            Schedules for Clinical Assessment of Neuropsychiatry
SCID-II         Structured Clinical Interview for DSM-III-R personality disorders
SD              Standard deviation
SNRI            Serotonin and norepinephrine reuptake inhibitors
SOFAS           Social and Occupational Functioning Assessment Scale for DSM-IV
SPSS            Statistical Package for the Social Sciences for Windows
SSI             Scale for Suicidal Ideation
SSRI            Serotonin-selective reuptake inhibitor
SUD             Substance use disorder
TCA             Tricyclic antidepressant
VDS             Vantaa Depression Study
WHO             World Health Organization
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1. ABSTRACT
This study forms part of a collaborative depression research project, the Vantaa
Depression Study (VDS), run by the Department of Mental Health and Alcohol Research of the
National Public Health Institute, Helsinki, and the Department of Psychiatry of the Peijas
Medical Care District (PMCD), Vantaa. The VDS is a prospective, naturalistic cohort study
of 269 secondary-level care psychiatric out- and inpatients with a new episode of DSM-IV
major depressive disorder (MDD).
Overall, the VDS involved screening 806 adult patients (aged 20-59 years) in the PMCD for
a possible new episode of DSM-IV MDD, and interviewing the 542 consenting patients with a
semistructured interview (the WHO Schedules for Clinical Assessment in Neuropsychiatry
[SCAN], version 2.0). Thereby, 269 patients with current DSM-IV MDD were included in the
study, and further interviewed with semistructured interviews to assess all other
psychiatric diagnoses as well. Exclusion criteria were DSM-IV bipolar I and II, schizoaffective
disorder, schizophrenia or another psychosis, organic and substance-induced mood disorders.
The outcomes of major depressive episode (MDE) and the comorbid disorders were
investigated at six and 18 months after baseline using repeated semistructured interviews.
The exact duration of the index episode and the timing of possible relapses/recurrences
were prospectively examined using a graphic life chart based on DSM-IV criteria and
definitions. Time after baseline was divided into three periods: (1) state of full
remission (none of the 9 MDE criteria symptoms), (2) state of partial remission (1-4 of
the 9 symptoms), or (3) state of MDE (5+ of the 9 symptoms). Besides symptom ratings and
visits to attending personnel, life-events during the follow-up were also asked about in
order to improve the accuracy of timing.
When presenting for psychiatric care, a typical psychiatric patient with MDD suffered from
many comorbid disorders; over half had current comorbid anxiety disorders (57%), nearly
half personality disorders (44%), and a quarter alcohol use disorders (25%). Only one
fifth (21%) had pure depression without any comorbid disorder.
Achieving full remission took about eight months, so despite the use of the new
antidepressants the outcome of MDD appears not to have improved in psychiatric care.
Although patients typically responded early to the treatment (most in 4 to 8 weeks), the
major problem was the long period with only partial remission, during which functional
impairment and depressive symptoms persisted, albeit at a milder level. In addition, about
40% of the patients had a recurrence of MDD during the 18 months, although these new
episodes were milder and shorter than the index episode. Numerous factors predicted the
duration of MDE to some extent, but severity of depression and current comorbidity were
14
the two most robust predictors. Severity of depression was also a significant predictor of
recurrence. There appeared to be no major differences in current comorbidity or course of
depression between melancholic and non-melancholic patients. Moreover, the consistency of
DSM-IV melancholic features across episodes appeared weak.
Most depressive patients in psychiatric care were found to be receiving adequate
antidepressant (88%) and psychotherapeutic treatments (98%) in the early acute phase, and
to have favourable attitudes towards them. Nevertheless, antidepressants were terminated
too early in about half of the patients, often following their autonomous decision. About
a third of the patients not achieving full remission were without any psychosocial
treatment at 18 months. Negative treatment attitudes were more common towards
antidepressants than psychosocial treatments, and tended to predict premature termination.
Summing up, the main challenge in psychiatric care appears to be continuity of treatments.
Without adequate continuity it is impossible to provide treatment that meets standards in
practice guidelines. In this task, however, collaborative work and shared responsibilities
between primary and secondary care are essential, and developing regional cooperation is
an inevitable challenge.
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3. INTRODUCTION
Depressive feelings as a response to loss or painful events are part of human life. This
normal affect of depression is self-limited and does not significantly interfere with a
person’s functional capacity. As an illness, however, major depressive disorder (MDD)
imposes a substantial burden by inflicting continuous pain and suffering on individuals
and their families. It is a highly prevalent, aetiologically multifactorial, clinically
heterogeneous and severe illness characterized by sad mood and inability to experience
pleasure, usually including serious abnormalities in cognition and physiological function.
MDD is also one of the most important mental disorders in terms of public health impact.
About a fifth of the population (Kessler et al., 1994; 2003), women more often than men,
will experience a clinically significant episode of MDD at some point in their lives. MDD
involves a marked risk of functional disability (Hays et al., 1995; Murray & Lopez, 1997;
Rytsälä et al., in press), self-destructive behaviour and premature death (Harris &
Barraclough, 1997; Sokero et al., 2003), and adversely affects interpersonal relationships
(Wade & Cairney, 2000). The risk of completed suicide among patients with MDD is about
20-fold (Harris & Barraclough, 1997; Hoeyer et al., 2000; Ösby et al., 2001), and
depression is associated with limitations in daily functioning and well-being comparable
to those in chronic medical conditions (Hays et al., 1995). By 2020, depression has been
predicted to become, after ischaemic heart disease, the major cause of disability
worldwide (Murray & Lopez, 1996).
The high disease burden is also understandable from consideration of the nature and course
of depression. Previously viewed as an acute and self-limiting illness, it is now clear
that depression is not only highly prevalent but also a chronic, recurrent and comorbid
illness. Following this paradigm shift in the concept of depression, studies of the
natural history of MDE have come to be seen as essential for further understanding the
nature of the disorder and developing more effective treatment strategies (Judd, 1997).
Although the comorbid form of MDD is highly prevalent (Kessler et al., 1996b; 2003), there
is only one study reporting concurrent prevalences of major categories of axis I disorders
(Sanderson et al., 1990), and none reporting overall current comorbidity with all axis I
and II disorders. Nor has the effect of overall comorbidity on the length of MDE or risk
of recurrence been systematically investigated. Furthermore, much of what we now accept
regarding the course of depression and its comorbidity is derived from studies based on
selected samples, e.g. inpatients, patients of tertiary level university clinics, and
samples predating the era of the current new antidepressants and the now widespread use of
maintenance therapies.
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As well as causing enormous individual suffering, depression also imposes a substantial
burden in terms of the costs to society caused by disability and loss of productivity.
Despite this, it is known from epidemiological studies that most depressive persons in the
general population receive inadequate treatment, or none at all (Kessler et al., 2003;
Hämäläinen et al., 2004). Studies in primary care indicate that depression commonly goes
unrecognized (Pignone et al., 2002), and treatment for it often fails to meet evidence-
based treatment guidelines (APA, 2000; Suomen Psykiatriyhdistys, 2004) for either drug
therapy or psychotherapy (Gilbody et al., 2003; Kessler et al., 2003). Moreover, even in
psychiatric care it is still largely unknown how the treatment provided meets the
standards of these guidelines (Young et al., 2001), and which are the factors that predict
treatment inadequacy, premature termination and non-adherence among depressive patients.
The Vantaa Depression Study (VDS) is a prospective, naturalistic cohort study of 269
secondary-level care psychiatric out- and inpatients with a new episode of DSM-IV MDD. In
the VDS the predictors of chronicity, recurrences, suicide attempts as well as functional
and work disability are investigated, and the adequacy of treatments evaluated. The
present thesis focuses on current comorbidity, outcome and treatments received among
depressive patients followed up for 18 months.
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4. REVIEW OF THE LITERATURE
4.1 Diagnosis of major depressive disorder (MDD)
The current psychiatric classifications are categorical systems that divide mental
disorders into types based on sets of criteria with defining features. The naming of
categories has been the fundamental approach used in all systems of medical diagnosis
(Kaplan & Sadock, 1998). Categorical diagnoses possess many strengths: they are a quick
short-hand for clinicians, and they often lead to well-defined treatments, and statements
about prognosis (Goldberg, 1996; Kendell & Jablensky, 2003). However, it is also likely
that disorders as currently diagnosed represent a heterogeneous set of disorders with
multiple causes (Kaplan & Sadock, 1998; Charney & Manji, 2004). Diagnostic classification
should not be applied mechanically and without using clinical judgment. The
classifications currently in use are the Diagnostic and Statistical Manual of Mental
Disorders (DSM) (APA, 1987; 1994; 2000) and the International Statistical Classification
of Diseases and Related Health Problems (ICD) (WHO, 1992; 1993; Tautiluokitus, 1996). In
DSM-IV, unipolar forms of primary mood disorders are divided into three groups: MDD,
dysthymic disorder, and depression not otherwise specified. Mood disorders are generally
defined as an illness characterized by different combinations of several co-occurring
symptoms for a defined period of time contributing to significant psychosocial impairment
or marked distress (APA, 1994; 2000; WHO, 1992; 1993). MDD is characterized by one or
more major depressive episodes lasting at least two weeks. Persistent depressive mood or
significant loss of interest or pleasure is the required core symptom, which must be
accompanied by at least four associated symptoms (total of 5 symptoms), such as
significant weight change, insomnia or hypersomnia, psychomotor agitation or retardation,
fatigue or loss of energy, feelings of worthlessness or extreme guilt, decreased ability
to think or concentrate, and suicidal ideation or thoughts of death, in order to warrant a
diagnosis of MDD (APA, 1987; 1994; 2000). DSM-IV also lists three levels of severity of
MDD. Based on the number of criteria symptoms, the severity of the symptoms and the degree
of functional disability and distress, MDD can be mild, moderate or severe (with or
without psychotic features). Symptoms that are due to a general medical condition,
mood-incongruent delusions or hallucinations, or bereavement must be ruled out. The terms
and codes in DSM-IV are mostly compatible with ICD-10, and diagnosis of MDD is basically
similar in both classifications. However, compared with DSM-IV, ICD-10 splits one
criterion (feelings of worthlessness and unreasonable guilt), requires one symptom less
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for diagnosis,   and  also  includes  fatigue or loss of energy among the core symptoms.
Research programmes usually apply the DSM classification rather than ICD as it provides
more detailed guidelines for case definition. In this thesis, unless otherwise specified,
depression refers to unipolar DSM-IV MDD.
4.1.1 Melancholic features of MDD
Diagnosing the melancholic features of depression is seen to be important for identifying
a group of patients whom some studies indicate are more responsive to somatic therapies
(e.g. tricyclic antidepressants [TCAs] and/or eletroconvulsive therapy [ECT]). The term
melancholia was first operationally defined in the DSM-III criteria (APA, 1980), although
the Research Diagnostic Criteria (RDC; Spitzer et al., 1978) classification of endogenous
depression served as the model for these criteria. After DSM-III and DSM-III-R (APA, 1987)
appeared, several studies questioned the validity of the melancholia and melancholic type
criteria (Zimmerman & Spitzer, 1989; Zimmerman et al., 1989). The shorter DSM-III feature
listing, but with broadened and better defined criteria, was restored in the DSM-IV (APA,
1994; 2000). The DSM-IV melancholic features specifier includes either of the following:
A) loss of pleasure in all, or almost all, activities and lack of reactivity to
pleasurable stimuli, or B) three (or more) of the following: distinct quality of depressed
mood, depression regularly worse in the morning, early morning awakening, marked
psychomotor retardation or agitation, significant anorexia or weight loss, or excessive or
inappropriate guilt (APA, 2000). The validity of the DSM-IV criteria in differentiating
melancholic and non-melancholic depression has been criticized with the suggestion that
observable psychomotor disturbances are the only necessary and sufficient feature of the
definition of melancholia, whereas the other features are prevalent in both melancholic
and non-melancholic subjects and are thus nonspecific (Parker & Hadzi-Pavlovic, 1996;
Parker et al., 2000a; Parker, 2000; 2003).
The debate over whether melancholic or non-melancholic subtypes of depression represent
two aetiologically distinct syndromes or one syndrome differing only in severity
represents one of the important controversies in the classification of mental disorders
(Carney et al., 1965; Kendell, 1976; Zimmerman & Spitzer, 1989; Rush & Weissenburger,
1994; Kendler, 1997; Parker, 2000), and concerns the descriptive as well as the construct
validity of these models. The currently dominant classificatory model of depression is
unitarian, defining it as a single entity varying only in severity, rather than
distinguishing between melancholic and non-melancholic, or more illness types (Parker,
2000).
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4.1.2 Atypical features of MDD
The term atypical was first used to describe a type of depression that responded well to
monoamine oxidase inhibitors (MAOIs), and less well to TCAs and ECT (West & Dally, 1959;
Sargant, 1961). The validity criteria of the atypical features subtype has been
questioned, and the decision to include this subtype in the DSM-IV was controversial
(Spitzer & Williams, 1982; Posternak & Zimmerman, 2002). Nevertheless, according to
DSM-IV (APA, 1994) the current atypical subtype of MDD comprises five features: mood
reactivity plus at least two of the following four symptoms: hypersomnia, either increased
appetite or weight gain, severe lethargy ("leaden paralysis"), and a pathological
rejection sensitivity.
4.2 Prevalence of MDD in general populations
The prevalence of depressive disorders in general population has been estimated in
numerous epidemiological studies, and recently in a survey covering almost the whole word
(WHO World Mental Health Survey Consortium, 2004). Experience, however, suggests that
depression prevalence comparisons should be treated with caution. The variations in time
frames, age ranges, diagnostic criteria and interview schedules (DIS, CIDI) complicate the
synthesis of findings. In addition, the portability of major depression diagnostic
criteria across countries requires further confirmation (Patten, 2003). However, studies
on epidemiological samples generally indicate that depression is highly prevalent in the
general population (Kessler et al., 1994; 2003; Ayuso-Mateos et al., 2001; Jacobi et al.,
2004). It has been estimated that about a fifth of the population (Kessler et al., 1994;
2003), women more often than men, will experience a clinically significant MDE at some
point in their lives, and up to 75-85% of these subjects go on to have a recurrence during
their lifetime (Angst, 1986; 1995a; Mueller et al., 1999; Keller & Boland, 1998).
The National Comorbidity Survey Replication (NCS-R), conducted in 2001-2002, found a
lifetime prevalence of MDD of 16.2% and a 12-month prevalence of 6.6% among US adults
(Kessler et al., 2003). The Mental Health Supplement of the German National Health
Interview and Examination Survey (GHS-MHS) reports the lifetime prevalence of any unipolar
depression to be 17.1%, and the 12-month prevalence 10.7%, in the German population
(Jacobi et al., 2004). In Finland, the Health 2000 project reports the 12-month prevalence
of MDD to be 4.9% (Pirkola et al., in press), while the prevalence was found to be 9.3% in
the Finnish Health Care Survey (Lindeman et al., 2000). The use of a diagnostic interview
with stringent exclusion criteria probably explains the lower prevalence in the more
recent Health 2000 project (Pirkola et al., in press). The Mini Finland Health Survey
reported that only one third of those diagnosed with depression were actually receiving
treatment, although they were assessed to be in need of it (Lehtinen et al., 1990;
Lehtinen & Joukamaa, 1994). However, only about a half of those suffering from depression
in Finland perceive a need for mental health services (Isometsä et al., 1997). The Finnish
21
Health Care Survey (Hämäläinen et al., 2004) also found that a considerable proportion
(41%) of patients with even the most severe depression were not receiving any treatment.
Among US adults in the NCS-R, health care treatment for depression was adequate in only a
fifth of the cases with 12-month MDD (Kessler et al., 2003).
4.3 Aetiology of MDD
4.3.1 Multifactorial model
MDD is a multifactorial, clinically heterogeneous disorder with a wide range of possible
aetiological factors (Kendler, 1993, 2002). The concept of depression has shifted from one
where genetic, biological, developmental and environmental risk factors were thought to be
unrelated and to define a particular clinical syndrome, to one where these risk factors
are seen to be related and interacting (Goodyer et al., 2000; O’Keane, 2000; Kendler et
al., 2002; 2004; Caspi et al., 2003; Charney & Manji, 2004). Based on this concept an
individual’s probability of suffering from a MDD is affected by many factors, including
predisposing genetic influences (Sullivan et al., 2000; Caspi et al., 2003; Korszun et al.,
2004; Lesch, 2004), exposure to early adverse experience such as maternal stress during
pregnancy (Oates, 2002; O’Connor et al., 2002), parental depression (Lyons-Ruth et al.,
1986; 2002; Lieb et al., 2002), childhood physical or sexual abuse (Heim et al., 2000;
Gladstone et al., 2004), loss of a parent (Tennant, 1988), predisposing personality traits
(Boyce et al., 1991; Caspi et al., 1996; Kendler et al., 2004), anxiety (Kessler et al.,
1996b; Young et al., 2004), low social support (Cooper & Paykel, 1994), recent stressful
life events (Paykel et al., 1969; Brown & Harris, 1978, Kendler et al., 2004), and many
hormonal and neurobiological influences (Arborelius et al., 1999; Sapolsky, 2000; Young et
al., 2000; Manji et al., 2001). However, aetiological risk factors for MDD are not
necessarily similar to factors affecting the outcome and course of the disorder.
There is also growing evidence that, far from being a disorder with purely psychological
manifestations, MDD is a systemic illness with damaging effects on multiple organ systems
(Manji et al., 2001; Insel & Charney, 2003). It has been associated with alterations in
endocrine, cardiovascular and immune systems, as well as in bone metabolism (Michelson et
al., 1996; Musselman et al., 1998; 2003; Jiang et al., 2002), and appears to have adverse
effects on comorbid medical diagnoses, such as coronary artery disease, stroke, diabetes
and osteoporosis (Frasure-Smith et al., 1993; Michelson et al., 1996; Vataja et al., 2001;
Lustman & Clouse, 2002; Carney & Freedland, 2003; Frasure-Smith & Lesperance, 2003).
Generally, evidence from research indicates that depression and vascular disease have a
bi-directional association, especially in the elderly (Thomas et al., 2004). Depression
has also been linked to memory deficits (impairments in verbal declarative memory)
associating with a hippocampal dysfunction (Bremner et al., 2004; Vythilingam et al.,
2004).
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4.3.2 Heritability and genetic risk factors
Heritability for depression is usually reported to be in the 20-45% range (Sullivan et
al., 2000; Wallace et al., 2002), but even 70% has been reported (Lesch, 2004). In a
recent meta-analysis (Sullivan et al., 2000) first-degree relatives of depressed subjects
had a nearly three-fold increase in their risk for MDD compared with the general
population. Linkage studies in unipolar depression have also been published recently, and
these suggest a number of candidate regions on different chromosomes (Abkevich et al.,
2003; Zubenko et al., 2003; Holmans et al., 2004). Although MDD undoubtedly has a genetic
basis, there is now compelling evidence that even early life stress constitutes a major
risk factor for the subsequent development of depression. The emerging evidence suggests
that a combination of genetics, early life stress and ongoing stress may ultimately
determine individual responsiveness to stress and vulnerability to depression (Caspi et
al., 2003). Findings by Caspi et al. (2003) suggest that childhood maltreatment interacts
with allelic variation of 5-HTT expression and function (polymorphism in the 5’-flanking
transcriptional control region of the 5-HTT gene [5HTTLPR]) increasing the vulnerability
to developing mood disorders, and that emotionality and stress reactivity can be
influenced by experiences early in life. Moreover, this allelic variation of 5-HTT
expression and function is also associated with personality traits of negative
emotionality, including anxiety, neuroticism and agreeableness (Lesch et al., 1996;
Greenberg et al., 2000). Interestingly, some recent functional imaging studies of the
brain report that serotonin transporter polymorphism also associates with reduced
hippocampal volume (Frodl et al., 2004), or with greater amygdala neuronal activity
(Hariri et al., 2002; Hariri & Weinberger, 2003). These findings confirm that genetically
driven variation of serotonergic function might contribute to the response of brain
regions underlying emotional behaviour.
4.3.3 Structural, functional and neurochemical findings
Recent studies have investigated potential structural brain changes in depression, and
there is now evidence demonstrating reductions in the prefrontal cortex (Botteron et al.,
2002; Bremner et al., 2002; Hastings et al., 2004), amygdala (Hastings et al., 2004), and
hippocampus (Mervaala et al., 2000; Campbell et al., 2004; Videbech & Ravnkilde, 2004), as
well as regional reductions in the numbers and/or sizes of glia and neurons. Activation of
the hypothalamic-pituitary-adrenal (HPA) axis seems to have a role in mediating
stress-induced neuronal changes (Sapolsky, 2000), and it has been suggested that
aberrations in the corticotrophin releasing factor (CRF) carry most of the responsibility
for HPA-axis hyperactivity (Arborelius et al., 1999), and thus hypersecretion of cortisol.
In addition to directly causing neuronal atrophy, life stress and glucocorticoids also
reduce cellular resilience (Manji et al., 2001). It is also likely that genetic factors
contribute not only to neurochemical alterations, but also to the impairments of cellular
plasticity and resilience observed in MDD (Manji et al., 2000; 2001; 2003). Actually,
modifications in the expression of genes related to neurotransmission, survival of
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neuronal and glial cells, and signal transduction have been recently identified (Knable et
al., 2002; 2004). Neurotrophic signalling cascades involved in regulating neural
plasticity, resilience and neurodegeneration may have a particularly important role in
explaining the aetiology of depression (Manji et al., 2000; 2003; Charney & Manji, 2004),
as well as the response to antidepressants (Manji et al., 2000; 2003; Popoli et al., 2002;
Harvey et al., 2003; Charney & Manji, 2004).
4.4 Comorbidity of MDD
4.4.1 Definition of the concept
Comorbidity refers to the occurrence of two or more distinct disorders in a person in a
defined period of time (Klerman, 1990). The concept of comorbidity has its origin in
general medicine (Feinstein, 1970), but has also been increasingly applied in psychiatry
(Klerman, 1990; Wittchen, 1996; Keller et al., 1996a), largely as a consequence of the
introduction of the explicit descriptive, operational criteria for mental disorders
(Feighner, 1972; Spitzer et al., 1978; APA, 1980). In particular, DSM-III (APA, 1980)
supported the use of multiple diagnoses within a multiaxial classification system, and
comorbidity has even been criticized for being an artefact produced by the categorical
diagnostic classification systems (Klerman, 1990; Tyrer, 1995). Non-comprehensive
definitions of comorbidity, variations in diagnostic assessments, timing of diagnosing,
time-frame (e.g. lifetime or current), and different health care settings have led to
substantial discrepancies in reported prevalences of comorbid disorders, producing a
rather complex picture of their significance (Weiss et al., 1992; Zimmerman, 1994; Tyrer,
1995; Wittchen, 1996; Griez & Overbeek, 1997; Bogenschutz & Nurnberg, 2000; Vella et al.,
2000).
The diagnostic categorical approach makes the strict assumption that a comorbid disorder
is present or absent according to the presence or absence of specified criteria (Wittchen,
1996). The categories of disorder are very useful to practicing clinicians; for example,
they provide information about the likelihood of recovery, and guide decisions about
treatment (Goldberg, 1996; Kendell & Jablensky, 2003). However, many have argued for
dimensional models, especially for personality disorders (Shea, 1995). There is actually
growing evidence that the dimensional approach may be useful, and a dimensional rather
than categorical approach to defining the depressive phenotype has recently been used for
identifying susceptibility genes (Hasler et al., 2004; Korszun et al., 2004) and risk
factors predicting suicidality (Verona et al., 2004). Moreover, the greater stability of
comorbid anxiety and depression than either disorder alone, and the substantial
persistence of subthreshold levels of these disorders has also been reported in an
epidemiological sample (Merikangas et al., 2003). Interestingly, in their vision of the
future Hasler and colleagues (2004) propose to dissect the behavioural phenotypes into key
components, and integrate specific environmental risk factors and neurobiological
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endophenotypes into the new classification system. Thus, in order to find possible
connections between various accumulating symptoms, personality traits and features
(Cloninger, 1987; 1993; Eysenck, 1987), and to establish better, genetically relevant
depressive phenotypes (Hasler et al., 2004), our thinking should go beyond the categorical
approach. Therefore, when assessing comorbidity, categorical and dimensional approaches
should be allowed to coexist, and symptom patterns and subthreshold conditions may also be
useful and informative. In this study (I-IV), however, comorbidity refers to current
categorical (DSM-IV) diagnostic comorbidity.
4.4.2 Comorbidity of MDD in general populations
Numerous epidemiological studies and surveys have reported high comorbidity of depression
(Regier et al., 1990; 1998; Grant & Harford, 1995; Angst, 1996; Kessler et al., 1996a;
1996b; 2003), and the impact of this on both outcome and health services utilization
(Kessler et al., 1996a; Wu et al., 1999). Comorbid depression is more of a rule than
exception: nearly half of the subjects with MDD have a current anxiety disorder (Regier et
al., 1990; 1998; Kessler et al., 1996b), and about a fifth have a current substance use
disorder (SUD) (Regier et al., 1990; Grant & Harford, 1995; Kessler et al., 1996a). Only
about a fifth of cases with 12-month MDD had no axis I comorbid DSM-IV disorders in the
recent NCS-R study (Kessler et al., 2003).
The prevalence of personality disorders in a representative sample of the general
population has been reported to be between 6% and 13% (Samuels et al., 1994; Torgersen et
al., 2001). However, only one study has reported the prevalence of axis II disorders in a
community sample with depressive disorders, the overall prevalence being 22% (Casey et
al., 2004). In addition, calculating from the figures of the Baltimore site of the
Epidemiological Catchment Area (ECA) study (Samuels et al., 1994), a prevalence of 8% for
comorbid axis II disorders was obtained. The prevalence of axis II disorders among
subjects with lifetime MDD has varied between 23% and 47% in non-patient samples
predominantly comprising first-degree relatives of psychiatric patients (Zimmerman &
Coryell, 1989; Maier et al., 1992).
4.4.3 Comorbidity of MDD in clinical samples
While the construct validity of the concept of comorbidity of psychiatric disorders
remains controversial, there is nevertheless accumulating evidence of the clinical
significance of comorbidity in terms of treatment responses and overall clinical outcome.
Clinical studies have reported that comorbidity is one of the major factors associating
with poor outcome of MDD, by increasing the risk of relapse or recurrence (Alnaes &
Torgersen, 1997), chronicity (Keller et al., 1984; Mueller et al., 1994), residual symptoms
(Paykel et al., 1995), suicide (Fawcett et al., 1990; Cheng, 1995; Cheng et al., 1997;
Fawcett, 1997; Foster et al., 1999; Hansen et al., 2003) and psychosocial impairment (Van
Valkenburg et al., 1984; Rytsälä et al., in press). The current comorbidity pattern may
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also influence the choice of treatment modality, as suggested in the APA Revised Practice
Guideline for the Treatment of Patients with MDD (APA, 2000). In psychiatric settings, the
reported prevalences of current comorbid disorders among patients with MDD have varied
widely (Tables 1 and 2). Overall, about half of patients with MDD in psychiatric care also
have a current anxiety and personality disorder, and about one fifth a current substance
use disorder (Tables 1 and 2).
Many of the early studies focused on a single type of comorbid disorder, a design which
may well inflate the prevalence of comorbidity found. For example, the estimates for
prevalence of current panic disorder are two-fold higher (weighted mean 22%) in studies
focused solely on comorbid panic disorder (Van Valkenburg et al., 1984; Coryell et al.,
1988; Grunhaus et al., 1994) compared to studies (Sanderson et al., 1990; Fava et al.,
1996a; Schatzberg et al., 1998; Zimmerman et al., 2000) focusing on several comorbid
anxiety disorders concurrently (weighted mean 11%). The extent to which single type
studies overestimate prevalences may vary by the type of disorder. The possible
explanations for this phenomenon include less than perfect rule-outs in structured
interviews, biased patient samples, and publication bias favouring high prevalences.
Only one study on comorbidity of MDD has reported prevalences of major categories on axis
I disorders (Sanderson et al., 1990), and none has reported overall current comorbidity
with all axis I and II disorders. Moreover, variations in patterns of comorbidity in terms
of sociodemographic factors such as age, gender, marital status, education, income and
type of residential area, as well as clinical characteristics such as number of lifetime
depressive episodes, axis I by axis II, age at onset, and severity of depression, have
been relatively little investigated in clinical populations (Pfohl et al., 1984; Flick et
al., 1993; Golomb et al., 1995a; 1995b; Fava et al., 1996a; 1996b; Sato et al., 1996;
Comtois et al., 1999; McGlashan et al., 2000). Furthermore, most previous studies have
been conducted on inpatient populations in tertiary-level treatment centres, which might
affect the generalizeability of their findings to secondary-level psychiatric settings
because of the possibility of selection bias. In addition, almost all studies on
comorbidity of depression have been based on DSM-III-R criteria; very few have been DSM-IV
studies (Zimmerman et al., 2000).
4.5 Course and outcome of MDE
4.5.1 Methodological aspects in defining outcome
The lack of a standard and valid set of outcome definitions hinders study of the
naturalistic course of depressive disorders (Frank et al., 1991; Prien et al., 1991;
Keller, 2003; 2004). As descriptors for the clinical course of depressive illness, terms
such as remission, relapse and recurrence have been incoherently applied as measures of
outcome. The inconsistency of outcome definitions across studies leads to difficulties
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when comparing and interpreting results, and their relationship to clinical practice. The
first effort to achieve a terminology consensus was made by Frank et al. (1991), who
suggested conceptual definitions for MDD outcome. Unfortunately, and partly because of
incompatible and changing lengths of duration used for remission and recovery in these
criteria, they somewhat failed to achieve consistency (Keller, 2003).
Clinical experience indicates that remission is the optimal outcome of treatment (Keller,
2003; 2004), and very recently it has been proposed that remission as optimal should be a
completely asymptomatic state, with absence of both symptoms and functional impairment
(Keller, 2003). This standard for remission seems essential because the presence of
residual symptoms is considered a strong predictor of relapse or recurrence (Paykel et
al., 1995; Judd et al., 1998; 1999), a more chronic course of depression (Judd, 2000),
shorter time between episodes (Judd et al., 1998), decreased likelihood of recovery
(Keller et al., 1992), and impaired social functioning (Kennedy & Paykel, 2004). Thus, the
presence of even minimal residual symptoms may warrant continuation of treatment. By some
standards, however, patients may be considered in remission despite still having one or
two minor symptoms (Keller et al., 1982; 1983; 1992). In conclusion, as Keller has
recently stated, "currently there is not a universally accepted definition of remission"
(Keller, 2003).
4.5.2 Duration of MDE in general populations
Data on the duration of major depressive episodes in general populations are sparse.
However, a few studies (Sargeant et al., 1990; Lehtinen et al., 1993; Angst & Merikangas,
1997; Eaton et al., 1997; Spijker et al., 2002) suggest that the prognosis of depression in
a general population is somewhat better than in psychiatric care. In the ECA study, a
median duration of MDE of 8-12 weeks was found (Eaton et al., 1997), and recently Spijker
et al. (2002) reported a median duration of three months (95% CI 2.2-3.8). In the most
recent epidemiological report from the NCS-R (Kessler et al., 2003) the mean duration of
MDE was 16 weeks (95% CI 15.1-17.3). These MDEs fall into a lower range of duration than
found in clinical studies (Keller et al., 1982; 1992; Coryell et al., 1994; Angst &
Preisig, 1995; Solomon et al., 1997; Furukawa et al., 2000; Kennedy et al., 2003).
However, a rate of 20% for chronicity in a general population (Spijker et al., 2002) was
similar to findings in clinical populations (Keller et al., 1982; 1992; Coryell et al.,
1994; Angst & Preisig, 1995; Solomon et al., 1997; Furukawa et al., 2000; Kennedy et al.,
2003).
4.5.3 Outcome of MDD
On the basis of available studies of its outcome, MDD appears to be a chronic illness with
a high risk of recurrence over the lifetime. Prospective long-term (Angst 1986; Keller et
al., 1992; Angst & Priesig, 1995a; 1995b; Mueller et al., 1996; 1999; Keller & Boland,
1998; Solomon et al., 1997; 2000; Kennedy et al., 2003) and shorter-term outcome studies
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(Maj et al., 1992; Wells et al., 1992; Ramana et al., 1995; Parker et al., 2000b;
Sherrington et al., 2001; Myers et al., 2002), as well as retrospective long-term outcome
studies (Kiloh et al., 1988; Lee & Murray, 1988; Andrews et al., 1990; Thornicroft &
Sartorius, 1993; Surtees & Barkley, 1994; Brodaty et al., 2001) document high recurrence
and chronicity of major depressive episode. It seems that approximately eight out of ten
people experiencing MDE will have at least one more episode during their lifetime (Angst,
1986; Mueller et al., 1999), and about one fifth will have a chronic course of MDE lasting
≥2 years (Keller et al., 1992). Moreover, previous long-term studies have shown that
symptoms at sub-syndromal level are common and persist for many years after an episode of
MDD (Angst & Merikangas, 1997; Judd et al., 1998), even with antidepressant treatment
(Kennedy et al., 2004).
The tendency for patients in tertiary-level treatment centres to have undergone many prior
treatments may produce bias towards more chronic, severe and recurrent illnesses compared
with more unselected cohorts of MDD patients (Furukawa et al., 2000; Roy-Byrne et al.,
2000; Spijker et al., 2002; Kanai et al., 2003). Thus, the length of depressive episode
and rate of recurrence can be expected to vary by the level of treatment setting and
inpatient or outpatient status. In fact, several short-term (Kessler et al., 1985;
Sargeant et al., 1990; Ormel et al., 1993; Lin et al., 1998; Simon, 2000; Spijker et al.,
2002) and a few long-term (Coryell et al., 1991; Angst & Merikangas, 1997; Eaton et al.,
1997; van Weel-Baumgarten et al., 1998) outcome studies suggest that the prognosis of
depression is better in community and primary health care settings than in psychiatric
care. Moreover, the most influential outcome studies (Piccinelli & Wilkison, 1994; Judd,
1997) were undertaken during the past era of tricyclic antidepressants and before the
recommendation of continuation and maintenance treatments, which again somewhat
undermines the ability to generalize such findings to current psychiatric settings.
4.5.3.1 Clinical factors as predictors of outcome   
Preventing chronicity and recurrence of depressive episodes is the central aim of
treatment, and information on risk factors for chronicity and recurrences is important for
identifying patients at particularly high risk. Severity of the MDE, comorbid dysthymia
(double depression), and longer duration of index episode before entry have been
consistently associated with non-recovery or longer time to remission (Keller et al.,
1982; 1984; 1992; Ramana et al., 1995; Mueller et al., 1999; Parker et al., 2000b;
Solomon et al., 2000; Myers et al., 2002). Some studies have shown that severity of depression
predicts relapse (Ramana et al., 1995), while other have found that it does not (Keller et
al., 1983; Sherrington et al., 2001), and severity is a risk factor for partial remission
(Paykel et al., 1995). The presence of residual symptoms is further considered a strong
predictor of relapse or recurrence (Paykel et al., 1995; Judd et al., 1998; 1999), a more
chronic course of depression (Judd, 2000), shorter time between episodes (Judd et al.,
1998), a decreased likelihood of recovery (Keller et al., 1992), and impaired social
functioning (Kennedy & Paykel, 2004). The number of prior MDEs and longer duration of the
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MDE prior to entry have also predicted relapse/recurrence (Keller et al., 1982; 1983;
Coryell et al., 1991; Maj et al., 1992; Surtees & Barkley, 1994; Lin et al., 1998; Mueller
et al., 1999). Information on age and gender as risk factors for both chronicity and
recurrence is inconsistent (Keller et al., 1982; 1986; 1992; Sargeant et al., 1990;
Coryell et al., 1991; Keitner et al., 1992; Huges et al., 1993; Surtees & Barkley, 1994;
Zlotnick et al., 1996; Simpson et al., 1997; Solomon et al., 1997; Mueller et al., 1999;
Hoencamp et al., 2001; Myers et al., 2002; Kennedy et al., 2004). Sociodemographic factors
appear to have no significant effects on the outcome of MDD when depression severity and
level of functional status are controlled for (Wells et al., 1992; Mueller et al., 1996).
4.5.3.2 Comorbidity as a predictor of outcome in clinical studies    
Rates of non-recovery, recurrence and relapse among patients with MDD and comorbid
disorders are likely to be greater than among patients with depression alone. Depressed
patients with panic disorder or with higher symptom ratings of anxiety have shown a longer
time to recovery (Keller et al., 1986; Coryell et al., 1988; 1992; Clayton et al., 1991;
Keitner et al., 1992; Parker et al., 2000b). The US National Institute of Mental Health
(NIMH) Collaborative Depression Study (CDS) is the only study to have investigated the
effects of current comorbid alcoholism among patients with MDD, finding those with current
alcoholism to be only half as likely to recover from their MDE (Mueller et al., 1994).
However, there is surprisingly little information on current axis I comorbidity and risk
of relapse/recurrence in clinical cohorts of depressive patients. The CDS found some
anxiety syndromes, but not current alcoholism, to be associated with higher risk of
relapse (Coryell et al., 1992; Mueller et al., 1994).
In a few naturalistic outcome studies in which semistructured interviews for both MDD and
axis II disorders were used, personality disorders predicted longer time to remission
(Sato et al., 1993; Greenberg et al., 1995; Ilardi et al., 1997; Viinamäki et al., 2002;
2003), and risk of relapse (Alnaes & Torgersen, 1997; Ilardi et al., 1997). Convergently,
high neuroticism (Surtees & Wainwright, 1996; Gormley et al., 1999) and low self-esteem
(Andrew et al., 1993; Surtees & Wainwright, 1996; Sherrington et al., 2001) have also been
related to longer duration of MDE.
Overall, the available evidence on the effects of current comorbidity on outcome of MDD in
clinical cohorts is somewhat difficult to interpret because of several methodological
limitations. These include not using semi/structured interviews for both MDD and comorbid
disorders, or not controlling for the effects of additional comorbid disorders, or not
using life-chart methodology (and thus reporting only cross-sectional findings). A recent
review of personality pathology and outcome in MDD, while pointing out many
methodological problems in measurements, suggests that comorbid personality pathology
should not be seen as an impediment to good treatment response (Mulder, 2002).
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Although comorbidity in MDD is prevalent,  the effect of overall comorbidity on the length
of episode or risk of recurrence has not been systematically investigated. Furthermore,
prevalences of comorbid cases have been quite low in some earlier studies (Keller et al.,
1983; Mueller et al., 1999) compared with those reported in more recent clinical
investigations (Zimmerman et al., 2000).
4.5.3.3 Psychosocial factors as predictors of outcome   
Adverse life events, together with genetic vulnerability and temperament factors, are
likely to form one of the key domains of liability to MDD (Kendler et al., 1993; 2002;
2004), and interactions between these risk factors seem important. Stressful life events
leading to depression, and the declining association between life events and risk for MDD
with increasing number of previous MDEs may be moderated by genetic vulnerability (Kendler
et al., 2001; Caspi et al., 2003). However, studies investigating possible effects of
psychosocial factors on the outcome of MDD in psychiatric samples are relatively sparse.
Stressful life events and lack of social support are associated with worse outcome of
depression in community and some clinical studies (Coryell, 1988; Paykel, 1994), although
in most prospective studies of severe and recurrent depression little effect on time to
remission or subsequent relapse has been found (Andrew et al., 1993; Paykel, 1994;
Sherrington et al., 2001).
4.5.3.4 Melancholic subtype as predictor of outcome and stability of melancholic features  
Most outcome studies (Keller et al., 1984; 1986; Kiloh et al., 1988; Parker et al., 1992;
Ramana et al., 1995; Broadity et al., 2001; Kennedy et al., 2003) have found no difference
in outcome between endogenous/melancholic and non-melancholic depression, while some
have found a correlation between endogeneity and less favourable outcome (Lee & Murray,
1988; Duggan et al., 1991). In the Maudsley Study (Lee & Murray, 1988), the melancholic
subjects tended to have more severe episodes but better non-episode functioning.
One crucial aspect of descriptive validity of the DSM definition for melancholic
depression, i.e. longitudinal stability across illness episodes, has received little
attention. If the two subtypes correspond to two different disorders, then this dichotomy
should show stability over time (Coryell et al., 1994). The findings reported in earlier
studies (Kendell, 1974; Paykel et al., 1976; Young et al., 1987; Coryell et al., 1994) are
somewhat inconsistent. In the US NIMH CDS (Coryell et al., 1994) the RDC endogenous
subtype was stable among patients with primary depression, but not among those with
secondary depression. Overall, it has been suggested that the non-endogenous subtype may
become endogenous during subsequent episodes more frequently than the reverse development
(Rush & Weissenburger, 1994). A very recent study found no evidence that either symptoms
or subtype of recurrent MDD are stable across episodes (Oquendo et al., 2004).
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4.5.3.5 Atypical and psychotic subtypes as predictors of outcome    
Little is known about the course of MDD with atypical features. One study has reported
that patients with atypical features had longer (Asnis et al., 1995), and another shorter
episodes of depression (Kendler et al., 1996). It has also been reported that atypical
depressives tend to have a more chronic course compared with non-atypical patients in
clinical but not epidemiologically derived samples (Nierenberg et al., 1998). Psychotic
features have been associated with a more severe form of depressive illness with greater
levels of psychosocial impairment (Coryell et al., 1987; 1996; Lee &Murray, 1988).
4.6 Treatment of MDD
Several sets of evidence-based treatment guidelines have been published to improve
detection and treatment of major depressive disorder (Schulberg et al., 1998; Crismon et
al., 1999; Anderson et al., 2000; APA, 2000; Bauer et al., 2002; Suomen Psykiatriyhdistys,
2004). Effective treatments include antidepressant medications, psychotherapy, a
combination of medication plus psychotherapy, and ECT (Schulberg et al., 1998; Crismon et
al., 1999; Anderson et al., 2000; APA, 2000; Bauer et al., 2002; Suomen Psykiatriyhdistys,
2004), and guidelines suggest treatment should be continued until remission of symptoms
and normal level of functioning.
4.6.1 Antidepressant treatment
Adequate antidepressant treatment of MDD consists of an acute phase, during which
remission is induced, a continuation phase, during which remission is preserved, and a
maintenance phase, during which the vulnerable patient is protected against recurrence of
subsequent episodes (APA, 2000; Suomen Psykiatriyhdistys, 2004). In the acute phase
antidepressants should be provided as an initial primary treatment modality for mild to
severe MDD (APA, 2000; Suomen Psykiatriyhdistys, 2004). Because the effectiveness of the
various antidepressants is comparable, the selection of an antidepressant will largely be
based on its profile of side-effects, the safety or tolerability of these side-effects,
interactions with other medications, and patient’s preference. If at least moderate
improvement is not observed in the following six to eight weeks, there should be
reappraisal of the treatment regimen (APA, 2000; Suomen Psykiatriyhdistys, 2004). In the
continuation phase, i.e. the four to nine months following remission, patients should be
maintained on antidepressants. Following the continuation phase, maintenance phase
treatment should be considered to prevent recurrences (Viguera et al., 1998; APA, 2000;
Geddes et al., 2003; Nierenberg et al., 2003; Suomen Psykiatriyhdistys, 2004). The factors
that should be considered when deciding whether to use maintenance treatment include number
of prior episodes, presence of comorbid conditions, residual symptoms, suicidality,
psychotic features, certain functional impairments, possible side-effects, and patient
preference (APA, 2000).
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4.6.2 Psychosocial treatment
In the acute phase, a specific, effective psychotherapy (cognitive, behavioural,
interpersonal, psychodynamic) alone as an initial treatment may be provided for patients
with mild to moderate MDD (APA, 2000; Suomen Psykiatriyhdistys, 2004). Clinical features
that may suggest the use of psychotherapeutic interventions include the presence of
psychosocial stressors, intrapsychic conflict/interpersonal difficulties, or comorbid axis
II disorder (APA, 2000). There is increasing evidence to support the use of a specific
psychotherapy in the continuation and maintenance phases to prevent recurrences (APA,
2000; Nierenberg et al., 2003; Suomen Psykiatriyhdistys, 2004). Frequency of visits
usually decreases in the maintenance phase (APA, 2000; Suomen Psykiatriyhdistys, 2004).
4.6.3 Combination treatment
The combination of psychotherapy and medication is recommended for those with
psychosocial/interpersonal problems, or comorbid axis II disorder together with moderate
to severe MDD. Poor adherence to treatments may also warrant a combination of treatment
modalities (APA, 2000). In a recent systemic review Pampallona et al. (2004) concluded that
combined antidepressant therapy and psychosocial treatment is associated with a higher
improvement rate than pharmacotherapy alone.
4.6.4 Treatment adherence
The degree to which a patient follows a treatment regimen has been defined in a variety of
ways, and different terms have been used. Compliance has traditionally been referred to as
"the extent to which a person’s behaviour confirms to medical advice, and especially the
extent to which the patient takes the medications as described" (Bruer, 1982; Frank et al.,
1992), while adherence is defined as "patient acceptance of recommended health behaviours"
(Wright, 1993). The literature (Frank et al., 1992; Lingam & Scott, 2002; Nemeroff, 2003)
tends to prefer the term adherence as it may also remind clinicians to form a good
therapeutic alliance with the patient, and emphasises active rather than passive
participation of the patient in this process. Intervention studies have shown that
psychoeducation is an effective way to enhance treatment adherence by offering structured
and detailed information to patients about their treatments (Demyttenaere & Haddad, 2000;
Lin et al., 2003; Vergouwen et al., 2003). However, confusion about terminology in this
field remains somewhat unresolved (Lingam & Scott, 2002; Nemeroff, 2003), and the terms
"compliance" and "adherence" are still used interchangeably.
Practice guidelines suggest that psychiatrists should recognize patients’ non-adherence,
and encourage them to discuss any concerns regarding adherence (APA, 2000). The
components of communication to patients that have been shown to improve adherence include
reminding them of when and how often to take the medicine, the need for at least 2-4 weeks
32
before beneficial effects may be noticed, the need to take medication even after feeling
better, the need to consult with the doctor before discontinuing medication, and what to
do if problems arise (APA, 2000).
4.6.5 Studies on treatment adequacy and adherence
Primary care (Katon et al., 1995; Lin et al., 2000; Demyttenaere et al., 2001) and
retrospective database studies (Melfi et al., 1998; Claxton et al., 2000) have reported
frequent shortcomings in depression treatment, including inadequate follow-up of dosage
and monitoring of antidepressant treatment. However, few recent psychiatric care studies
have investigated the extent to which treatment recommendations, especially after the
immediate acute phase, are carried out (Ramana et al., 1999; Sirey et al., 1999; Simon et
al., 2001; Cuffel et al., 2003; Kennedy et al., 2003). Treatment received, and predictors
of treatment inadequacy and premature termination, are rarely reported, even though
premature termination of treatments is a great concern for clinicians.
Medication non-adherence is common; estimates of non-adherence for affective disorders
range from 10% to 60%, with a median of 40% (Lingam & Scott, 2002). However, according to
the recent review, only 1% to 2% of all publications on treatment of affective disorders explore
factors associated with medication adherence (Lingam & Scott, 2002). Part of this neglect
is explained by the unresolved confusion about terminology, and highly variable methods
(i.e. prescription counts, pill counts, appointments kept, drug/metabolite plasma
concentrations) used in measuring non-adherence (Demyttenaere et al., 2001; Lingam &
Scott, 2002; Pampallona et al., 2002; Demyttenaere, 2003).
Recent studies, although limited in number, show increasing attention being focused on
various risk factors for non-adherence, such as stigma, health-beliefs and negative
attitudes towards psychiatric treatments (Melfi et al., 1998; Demyttenaere & Haddad, 2000;
Demyttenaere et al., 2001; Sirey et al., 2001; Keller et al., 2002; Lingam & Scott, 2002;
Demyttenaere, 2003; Lin et al., 2003). However, the extent to which patients’ negative
treatment attitudes, fear of side-effects, perceived side-effects per se, comorbidity and
severity of depression influence premature terminations of treatments, or non-adherence,
is still poorly understood (Lingam & Scott, 2002; Pampallona et al., 2002; Demyttenaere,
2003).
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Table  1. Current Axis I comorbidity of major depressive disorder in psychiatric settings
_______________________________________________________________________________________________________________________
Study reference                N             Outpatients %             Sex/            Method                        %
                                                                       Females %     
_______________________________________________________________________________________________________________________
Any anxiety disorder    
Sanderson et al., 1990         197              100                      56            SCID (DSM III-R)              42
Pini et al., 1997              38               100                      75            SCID-P (DSM-III-R)            92
Schatzberg et al., 1998        85               38                       49            SCID-P (DSM-III-R)            29
Fava et al., 2000              255              100                      NR            SCID-P (DSM-III-R)            45
Zimmerman et al., 2000         373              100                      67            SCID (DSM-IV)                 57
Panic disorder    
Van Valkenburg et al., 1984    114               NR (in/outpatients)     44            semi-structured interview     27
                                                                                       (Feighner, DSM-III)
Coryell et al., 1988           523/387*          NR (mostly inpatients)   60            SADS (RDC)                    19
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              10
Grunhaus et al., 1994          176/136*          NR (in/outpatients)     71            SADS (RDC)                    34
Fava et al., 1996a             396               100                     66            SCID-P (DSM-III-R)            8
Schatzberg et al., 1998        85                38                      49            SCID-P (DSM-III-R)            7
Fava et al., 2000              255               100                     NR            SCID-P (DSM-III-R)            8
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 17
Generalized anxiety disorder   
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              20
Fava et al., 1996a             396               100                     66            SCID-P (DSM-III-R)            9
Fava et al., 2000              255               100                     NR            SCID-P (DSM-III-R)            10
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 15
Social phobia  
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              15
Fava et al., 1996a             396               100                     66            SCID-P (DSM-III-R)            26
Alpert et al., 1997            243               100                     55            SCID-P (DSM-III-R)            27
Schatzberg et al., 1998        85                38                      49            SCID-P (DSM-III-R)            13
Fava et al., 2000              255               100                     NR            SCID-P (DSM-III-R)            26
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 33
Simple  phobia    
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              2
Fava et al., 1996a             396               100                     66            SCID-P (DSM-III-R)            14
Schatzberg et al., 1998        85                38                      49            SCID-P (DSM-III-R)            5
Fava et al., 2000              255               100                     NR            SCID-P (DSM-III-R)            15
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 14
_______________________________________________________________________________________________________________________
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_______________________________________________________________________________________________________________________
Study reference                N             Outpatients %            Sex/             Method                        %    
                                                                      Females %     
_______________________________________________________________________________________________________________________
OCD
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              4
Fava et al., 1996a             396               100                     66            SCID-P (DSM-III-R)            4
Schatzberg et al., 1998        85                38                      49            SCID-P (DSM-III-R)            9
Fava et al., 2000              255               100                     NR            SCID-P (DSM-III-R)            5
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 10
PTSD 
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              0
Schatzberg et al., 1998        85                38                      49            SCID-P (DSM-III-R)            4
Zimmerman et al., 2000         373               100                     67            SCID (DSM-IV)                 13
Alcohol use disorders  
Sanderson et al., 1990         197               100                     56            SCID (DSM-III-R)              8
McDermut et al., 2001          373               100                     67            SCID (DSM-IV)                 9
_______________________________________________________________________________________________________________________
Only studies with 1) semistructured or standardized diagnostic interviews for both MDD and comorbid disorders, 2) sample size of at least 25 patients,
3) unipolar MDD as their main sampling inclusion criterion, 4) adult age, and 5) only studies conducted in psychiatric settings are included.
*= unipolar MDD
NR= not reported
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Table 2. Overall Axis II comorbidity of major depressive disorder in psychiatric settings  
_______________________________________________________________________________________________________________________
Study reference                N             Outpatients %            Sex/             Method                        %   
                                                                      Females %   
_______________________________________________________________________________________________________________________
Any personality disorder  
Kocsis et al., 1986            26 (39*)         100                      69 (69)       semi-structured interview     40
                                                                                       (DSM-III)                     (47)
Alnaes & Torgersen, 1988       289/97**         100                      71            SCID  (DSM-III)               86
                                                                                       SCID  (DSM-III)
Sanderson et al., 1992         197 (32***)      100                      56 (56)       SCID-P  (DSM-III-R)           50
                                                                                       SCID-II (DSM-III-R)           (69)
Stuart et al., 1992            59               100                      75            SADS (RDC)                    24
                                                                                       PDE (DSM-III-R)
Flick et al., 1993             352/165**        100                      60            SCID (DSM-III-R)              61
                                                                                       SCID-II (DSM-III-R)
Golomb et al., 1995b           316/117****      100                      66            SCID-P(DSM-III-R)             56
                                                                                       SCID-II (DSM-III-R)
Pepper et al., 1995            45 (97*)         100                      67 (75)       SCID (DSM-III-R)              18
                                                                                       PDE-R (DSM-III-R)             (60)
Sato et al., 1996              96               100                      57            SCID-P (DSM-III-R)            55
                                                                                       SCID-II (DSM-III-R)
Fava et al., 2002              384              100                      55            SCID-II (DSM-IV?)             64
_______________________________________________________________________________________________________________________
Only studies with 1) semistructured or standardized diagnostic interviews for both MDD and comorbid disorders, 2) sample size of at least 25 patients,
3) unipolar MDD as their main sampling inclusion criterion, 4) adult age, and 5) only studies conducted in psychiatric settings are included.
*
= including dysthymia and double depression
**
= patients with MDD
***
= double depression
****
= SCID II for 117 subjects; only the results of SCID II reported here; the older group was also included (mean age 49.2±5.8 years)
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5. AIMS OF THE STUDY
This study investigated current comorbidity, outcome and treatments received in a sample
of 269 MDD patients in secondary level psychiatric care.
The specific aims of the study were:
I     To comprehensively investigate current axis I and II comorbidity, and variations by
      clinical and sociodemographic factors, in a representative psychiatric sample.
II    To determine the outcome of MDE in a modern secondary-level psychiatric setting,
      and the influence of psychiatric and somatopsychiatric comorbidity plus psychosocial
      factors on the outcome.
III   To investigate and compare the stability, outcome and comorbidity of the melancholic
      versus non-melancholic subtype of MDD.
IV    To describe the quality and continuity of psychotherapeutic and antidepressant treatments
      received in acute, continuation and maintenance phases of MDD, patients’ self-reported
      level of adherence and treatment attitudes, and factors explaining these.
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6. METHODS
6.1 General study design
The VDS is a collaborative depression  research project between the  Department of Mental
and Alcohol Research of the National Public Health Institute, Helsinki, and the Department
of Psychiatry of the Peijas Medical Care District (PMCD), Vantaa, Finland. The catchment
area comprises the city of Vantaa (population 169 000 in 1997). The PMCD Department of
Psychiatry offers secondary care psychiatric services to all Vantaa citizens. These
include a psychiatric inpatient unit, a general hospital outpatient clinic, six community
mental health care centers - each covering a specified catchment area - and two day
hospitals.
6.2 Screening
The first phase of patient sampling for the VDS involved screening all patients in the
PMCD with a possible new episode of DSM-IV MDD between 1st February 1997 and 31st May
1998. During that period, every patient (N=806) aged 20-59 years 1) seeking treatment at,
2) being referred to, or 3) already receiving care and now showing signs of deteriorating
clinical state in the Department of Psychiatry but without a clinical diagnosis of ICD-10
schizophrenia or bipolar I disorder, was screened for the presence of depressive symptoms.
The screening instrument included the five screening questions for depression from the WHO
Schedule for Clinical Assessment in Neuropsychiatry (SCAN), Version 2.0 (Wing et al.,
1990). The Scale for Suicidal Ideation (SSI) (Beck et al., 1979) was also completed to
identify cases with moderate to severe suicidal ideation or plans. After either 1) a
positive response to any of the SCAN screening questions, or 2) a score of six or more in
the SSI, irrespective of the presence of depressive symptoms, the patient was fully
informed about the study project, and written informed consent requested. Of the 703
eligible patients, 161 (22.9%) refused to participate in the study, but 542 (77.1%) agreed
and gave written informed consent (Table 3). The patients who refused did not differ
significantly (P>.05) in age or gender from those who consented. The Ethics Committee of
Peijas Hospital approved the study on 2nd December 1996.
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Figure 1. Flow-chart of the sampling procedure in the VDS    
        Screening                 Negative
        N=806                     N=103
        Positive                  Not consenting
        N=703                     N=161
        Consenting                No MDD
        N=542                     N=273
        DSM-IV MDD
        N=269
Table 3. Methods in the Vantaa Depression Study    
_______________________________________________________________________________________________________________________
Timing of screening               Between February 1, 1997, and May 31, 1998
 
Catchment area                    City of Vantaa (population 169 000 in 1997)
Setting                           Department of Psychiatry of the Peijas Medical Care District, Vantaa, Finland
Target group                      All psychiatric patients aged 20-59 years
                                  1) seeking treatment
                                  2) referred to treatment, or
                                  3) already in treatment with an acute deteriorating clinical state
Excluded from screening           ICD-10 schizophrenia, bipolar I disorder
Screening procedure               a) The five screening questions for depression from SCAN, one positive, or
                                  b) The Scale for Suicide Ideation (SSI), a score of six or more
Screened total                    806
Screened positive                 703
Refusals                          161 (23% of the screened positive)
 
Diagnostic interview              After informed consent DSM-IV (axis I, SCAN), and
                                  DSM-III-R (SCID-II modified to DSM-IV)
Inclusion criteria                DSM-IV unipolar MDD with a new depressive episode
Excluded from study               DSM-IV bipolar I and II disorder, shizoaffective disorder,
                                  organic or substance-induced mood disorder
Diagnostic reliability            20 videotaped diagnostic interviews,
                                  kappa coefficient 0.86 (0.58-1.00); for comorbidity and melancholic MDD not tested
_______________________________________________________________________________________________________________________
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6.3 Baseline evaluation
6.3.1 Diagnostic measures
In the second phase of sampling, the 542 consenting patients were interviewed face-to-face
by a researcher using the WHO SCAN 2.0. The interviewers had all received relevant
training by a WHO certified training centre. They examined whether or not the current mood
episode fulfilled the criteria for (unipolar) DSM-IV MDD. All psychiatric and medical
records in the PMCD, including a standardized set of laboratory tests, were also available
at the interview. Patients currently abusing alcohol or other substances were interviewed
after two to three weeks of abstinence, in order to exclude substance-induced mood
disorders. On this basis, 269 patients were diagnosed with DSM-IV MDD and included in the
study. Diagnostic reliability was investigated using 20 videotaped diagnostic interviews;
the kappa coefficient for MDD was 0.86 [0.58-1.0] with 95% observed agreement rate.
The decision to include the patient in the study cohort was made by the researcher during
the interview, after which the entire SCAN interview was conducted to achieve a full
picture of axis I comorbid disorders. In addition, the Structured Clinical Interview for
DSM-III-R personality disorders (SCID-II) (Spitzer et al., 1987) was used to assess
diagnoses on axis II. Current axis III diseases were assessed via a self-report checklist
with 44 items (corresponding to ICD-10 diagnoses). However, only axis III diseases diagnosed
by a physician and currently being treated were included.
6.3.2 Exclusion criteria
Patients with a diagnosis of DSM-IV bipolar I or II disorder, shizoaffective disorder,
schizophrenia or another psychosis, organic or substance-induced mood disorder were
excluded from the study, even if they fulfilled the symptom criteria of current MDE (Table
3). So were the cases with a history of MDD if the current episode did not fulfill the
criteria of the disorder.
6.3.3 Observer and self-report scales
The 17-item Hamilton Rating Scale for Depression (HAM-D; Hamilton, 1960) and the 21-
item Beck Depression Inventory (BDI; Beck et al., 1961) were used to assess severity of
depression, the SSI suicidal behaviour; the Social and Occupational Functioning Assessment
Scale for DSM-IV (SOFAS; Goldman et al., 1992) functional level; the Interview for Recent
Life Events (IRLE; Paykel, 1983) life-events, and the Interview Measure of Social
Relationships (IMSR; Brugha et al., 1987) and the Perceived Social Support Scale -
Revised (PSSS-R; Blumenthal et al., 1987) social support. Self-report scales, in addition
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to the BDI, included the Beck Anxiety Inventory (BAI; Beck et al., 1988), the Beck
Hopelessness Scale (HS; Beck et al., 1974), the Social Adjustment Scale-Self Report
(SAS-SR; Weissman et al., 1976), and the Eysenck Personality Inventory (EPI; Eysenck &
Eysenck, 1964).
6.3.4 Melancholic subtype and neurotisicm
The distinction between melancholic and non-melancholic depression was based on the SCAN
and DSM-IV criteria. The psychomotor symptoms (marked retardation or agitation) were
observed and rated as part of DSM-IV diagnostic assessments at baseline and follow-up
interviews. Neurotisicm was rated with the EPI. When analyzing stability of melancholic
features subtypes, only those patients who met the criteria for MDE at the time of the
follow-up interviews could be evaluated. Patients who remained with the full MDE criteria
for the whole follow-up period were excluded from these analyses.
6.3.5 Patients’ attitudes towards treatments
Attitudes towards antidepressant and psychotherapeutic treatments at baseline were
assessed separately by interview and rated on a Likert scale with the following items:
patient 1) actively wants treatment, 2) passively accepts treatment, 3) has reservations
about treatment, 4) has definitely negative attitudes towards treatment, or 5) could not
answer. At the follow-ups, patients were interviewed with scales comprised of the
following items: attitudes are 1) very positive, 2) positive, 3) neutral, 4) negative, 5)
very negative towards treatment, or 6) could not answer.
Patients with reservations about, or definitely negative attitudes towards treatments were
also asked their subjective reasons for these attitudes, with the following alternatives:
1) generally negative attitudes toward treatment, 2) fear of side-effects
(antidepressants) / not wanting to confide in a stranger (psychotherapeutic treatments),
3) fear of dependence, 4) not knowing enough about treatment, 5) patient’s / other’s
negative earlier experiences of treatment, 6) negative information from media, 8) no
belief that treatment will help, 9) treatment too expensive, or 10) could not answer.
6.4 Follow-up procedure
Of the total of 269 subjects with current MDD initially included in the study, 40 subjects
were missing (N=229) at six months. Some of these were traced again for the 18-month
follow-up (N=207), so only 13% (35/269) dropped out from both follow-up interviews. The
patients whose diagnosis switched to bipolar disorder during the 18-month follow-up (5%,
13/269) were censored from the analyses, and eight patients died during follow-up. The
median times to follow-up interviews were 6.5 and 18.8 months for six- and 18-month
interviews, respectively.
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6.4.1 Study drop-outs
The drop-outs were significantly younger (median 31.2 vs. 42.3, Z=-3.32, P=.001), more
often living alone (19%, 24/125 vs. 8%, 11/131, χ2=6.33, df=1, P=.017), scored higher
on the EPI-neuroticism scale (median 20.0 vs. 18.0, Z=-2.17, P=.030), and were more likely
to have comorbid dysthymia (26%, 8/31 vs. 12%, 27/225, Fisher’s exact test, P=.049)
than those attending both follow-ups. Patients who dropped out did not differ
significantly (P>.05) in DSM-IV melancholic features from those who completed the follow-up.
In some analyses only those attending the 18-month follow-up were included; in this case
the drop-outs (bipolar cases excluded) were significantly younger (mean±SD, 35.7±10.2 vs.
41.0±11.1 years, t=3.24, df=254, P=.001), more often unemployed (53%, 31/58 vs. 35%,
68/193, χ2=6.20, df=1, P=.013), and had current comorbid psychiatric DSM-IV disorders
(mean±SD, 3.5±2.0 vs. 3.0±1.7, t=-2.08, df=254, P=.038), panic disorder (26%, 15/58 vs.
13%, 26/198, χ2=5.41, df=1, P=.020), and social phobia more often (29%, 17/58 vs.
17%, 34/198, χ2=4.14, df=1, P=.042) than those attending the 18-month follow-up. When
baseline treatments were compared, the only significant finding was that drop-outs were
without antidepressants more often (22%, 13/58 vs. 12%, 24/198, χ2=3.84, df=1, P=.050).
6.4.2 Outcome measures
After the baseline assessments, the patients were asked to complete the BDI each month for
six months. The outcome of MDD and the comorbid disorders was investigated at six and 18
months by SCAN 2.0 and SCID-II interviews. In addition, all observer- and self-report
scales were included at both follow-up assessments. All medical and psychiatric records
were also available.
6.4.2.1 Life-chart methodology   
The exact duration of the index episode and the timing of possible relapses/recurrences
were examined by gathering all available data, which were then integrated into the form of
a graphic life chart. This was created at the six- and 18-month interviews after reviewing
with the patient all the information from the follow-up period. Besides symptom ratings
and visits to attending personnel, change points in the psychopathologic states using
probes related to important life-events were also asked in order to improve the accuracy
of assessment.
The life-chart was based on DSM-IV criteria and definitions. Time after the first baseline
interview was divided into three periods: (1) state of full remission (none of the 9 MDE
criteria symptoms), (2) state of partial remission (1-4 of the 9 symptoms), or (3) state
of MDE (5+ of the 9 symptoms). As a categorical variable, remission (further specified as
full or partial) was defined according to the DSM-IV, as at least two consecutive months
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in which criteria for a MDE were not met. Patients were considered to have achieved full
remission if they had spent at least two consecutive months in the state of full
remission, and partial remission if they had spent at least two months in the state of
partial remission. Relapse was defined as return of symptoms fulfilling the DSM-IV
criteria for MDE after a period of less than two months (but more than 2 weeks) with
symptoms below the MDE threshold. Recurrence was defined as in the DSM-IV definition for
296.3x MDD, as a return of symptoms sufficiently severe to satisfy criteria for an MDE
after at least two consecutive months of partial or full remission.
6.4.3 Definitions of duration of the index episode
Two alternative definitions for duration of the index episode after the first baseline
interview were used: (1) the uninterrupted duration of the episode in the state of MDE
(Time with full MDE criteria), and (2) time to the first onset of state of full remission
lasting at least two consecutive months (Time to full remission).
6.5 Treatments provided and their continuity
Psychotherapeutic support comprised regular appointments with a mental health professional
aimed at helping the patient by discussing her/his problems (weekly psychotherapy
excluded). Weekly psychotherapy was defined as weekly therapy sessions for ≥ four weeks
with a qualified, certified therapist (usually with psychodynamic, sometimes
cognitive-behavioural training). The adequacy of antidepressant dosage was defined as the
usual adult doses in the APA Practice Guidelines (APA, 2000). Continuity of
psychotherapeutic and antidepressant treatment was assessed by interviewing patients and
investigating all clinical information on treatment, including medical and psychiatric
records. Treatment was defined as ongoing as long as it was provided/prescribed according
to psychiatric records, while termination was the date when treatment was first documented
as not ongoing (or reportedly terminated by the patient if no later contact with a
professional). Here, sequential antidepressant trials and their intermediate short
wash-out periods were classified as one continuous treatment period.
6.5.1 Self-reported reasons for discontinuing
Patients were asked their subjective reasons for discontinuing antidepressants, with the
following alternatives: 1) poor/no response, 2) side-effects, 3) too expensive medication,
4) no need for treatment because of recovery, 5) patient’s autonomous decision, and 6)
could not answer.
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6.5.2 Self-reported treatment adherence
Self-reported treatment adherence concerning the treatments provided was investigated by
interviewing patients at the follow-ups using a Likert scale with the following response
items: has the patient come to sessions/been on antidepressants 1) regularly, treatment
compliance adequate with respect to treatment goals, 2) somewhat irregularly, it is
unclear whether this would affect treatment goals, 3) very irregularly, the treatment did
not proceed according to plan, and 4) not at all, the provided treatment could not be
implemented.
6.6 Data analyses
The Pearson chi-square statistic with Yates’ continuity correction test, and Fisher’s
exact test were used to evaluate categorical and non-parametric data, the Mann-Whitney or
Kruskal-Wallis test to compare continuous variables not normally distributed, and the
two-sample t-test for continuous variables normally distributed. Logistic regression
models were used to adjust for confounding factors. The Kaplan-Meier survival curves were
used to estimate the probability of remaining ill, and on an antidepressant during the
18-month follow-up. Cox proportional hazards models (Cox, 1972) were used in the analyses
for predicting time to symptom state below MDE criteria or to full remission. In these
analyses, censored data included the subjects who (1) had not achieved a symptom state
below the MDE criteria or (2) had not met the criteria of full remission by the end of the
follow-up period or by the time they left the study, or their diagnosis had switched to
bipolar disorder. Treatment received was reported separately for patients with full,
partial and no remission from the index episode because of the tendency of sicker patients
to receive more treatment in a naturalistic study (Sturm, 1999). Only those who completed
the whole 18-month follow-up could be included in analyses of the risk of recurrences,
stability of MDD subtypes, and treatments provided during the follow-up. In hypothesis
testing a p-value <.05 was considered significant, and p-values between 0.05 and 0.10 were
reported as trends. Odds rations with 95% confidence interval not including 1 were
considered significant. SPSS software, versions 9.0 or 11.0, was used (SPSS, 1999; 2001).
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7. RESULTS
7.1 Current comorbidity of psychiatric disorders in MDD (Study I)
7.1.1 Clinical and demographic characteristic of the sample
The majority of the patients in the MDD cohort were females (73%), and outpatients (83%),
half (50%) were married or cohabited, and 60% currently employed. Of the cohort patients,
36% met the criteria for DSM-IV melancholic features, while 64% had the non-melancholic
subtype (Table 4). The melancholic depressive patients were significantly more often
inpatients, had more severe depression, and lower level of functional capacity. There were
no statistically significant differences in age, gender, psychotic features, current
employment or marital status between patients with melancholic and non-melancholic
features (III: Table 1).
7.1.2 Current overall comorbidity
Most (79%) of the patients suffered from at least one current comorbid disorder, and the
majority (54%) from two or more. Over half (57%) had an anxiety disorder, a quarter (25%)
alcohol abuse or dependence, and nearly half (44%) at least one personality disorder (PD)
diagnosis (Figure 2).
7.1.3 Variations of comorbidity by sociodemographic and clinical factors
7.1.3.1 Axis I and axis II   
The anxiety disorders (OR 2.36, 95% CI 1.05-5.30), especially panic disorder (OR 2.37, 95% CI
1.03-5.45), as well as alcohol dependence (OR 3.08, 95% CI 1.30-7.50) associated significantly
with cluster B PDs, whereas social (OR 3.05, 95% CI 1.58-5.88) and specific phobia (OR 1.84,
95% CI 1.00-3.39) and agoraphobia without panic disorder (OR 2.85, 95% CI 1.27-6.37)
associated with cluster C PDs when age, gender and other clusters were controlled for in
logistic regression (I: Table 4).
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Table 4. Sociodemographic and Clinical Characteristics in Vantaa Depression Study a
                  
_______________________________________________________________________________________________________________________
Characteristics                Females (N=197)            Males (N=72)                 Total (N=269)   
_______________________________________________________________________________________________________________________
                               Mean      SD               Mean      SD                 Mean      SD   
Age (years)                    39.5      11.4             39.9      10.0               39.6      11.1
Age at onset of
first MDE (years) a            31.6      12.6             31.5      12.4               31.6      12.5
The 17-item HAM-D              19.7       5.6             19.0       6.8               19.5       5.9
The 21-item BDI                28.2       8.4             26.3       8.9               27.7       8.6
                               N         %                N         %                  N         %   
Outpatients                   165        84               58        81                223        83
Inpatients                     32        16               14        19                 46        17
Marital status
    Unmarried                  43        22               17        24                 60        22
    Married or cohabiting      99        50               36        50                135        50
    Divorced                   49        25               17        24                 66        25
    Widowed                     6         3                2         3                  8         3
Residential area b
     East                     125        63               43        61                168        63
     West                      72        37               28        39                100        37
Currently employed c          113        59               44        62                157        60
Family income d
    Low                        91        51               25        39                116        48
    High                       87        49               39        61                126        52
Total no of lifetime MDEse
    1(intake)                  72        37               21        30                 93        35
    2                          58        30               25        35                 83        31
    3 or more                  66        34               25        35                 91        34
Axis I diagnosis  
Dysthymia                      21        11               11        15                 32        12
Any anxiety disorder          118        60               34        47                152       57f
Panic disorder                 36        18                9        13                 45        17
Agoraphobia w/o panic          26        13                5         7                 31        12
Social phobia                  39        20               14        19                 53        20
Simple phobia                  52        26               16        22                 68        25
OCD                            15         8                3         4                 18         7
GAD                            24        12               13        18                 37        14
PTSD                            2         1                0         0                  2         1
Bulimia nervosa                 2         1                0         0                  2         1
Any alcohol use disorder       38        19               28        39                 66       25g
     Dependence                23        12               15        21                 38        14
     Abuse                     15         8               13        18                 28       10h
_______________________________________________________________________________________________________________________
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_______________________________________________________________________________________________________________________
Characteristics                Females (N=197)            Males (N=72)                 Total (N=269)   
_______________________________________________________________________________________________________________________
                               N         %                N         %                  N         %   
Axis II diagnosis 
Cluster A                      34        17               17        24                 51        19
     Paranoid                  31        16               16        22                 47        17
     Schizoid                   4         2                1         1                  5         2
     Schizotypal                0         0                0         0                  0         0
Cluster B                      31        16                8        11                 39        14
     Antisocial                 2         1                2         3                  4         2
     Histrionic                 5         3                0         0                  5         2
     Borderline                25        13                7        10                 32        12
     Narcissistic               2         1                2         3                  4         2
Cluster C                      63        32               22        31                 85        32
     Obsessive compulsive      13         7                4         6                 17         6
     Dependent                 13         7                5         7                 18         7
     Avoidant                  49        25               15        21                 64        24
     Passive aggressive         7         4                6         8                 13         5
     Any personality disorder  87        44               31        43                118        44
     Pure MDD                  37        19               19        26                 56        21
     Melancholic features      72        37               25        35                 97        36
     Psychotic features        18         9                4         6                 22         8
_______________________________________________________________________________________________________________________
a
 All data shown as N and % unless otherwise noted ,b missing 0.4%; N=268; c missing 2.2%; N=263, d missing 10%; N=242,
e missing 0.7%, N=267, f χ2=2.95, df=1, P=.086,  g χ2=9.91, df=1, P=.002, h χ2=5.10, df=1, P=.024
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Females tended to have more anxiety disorders (Table 4) than males, and younger patients
(aged < 40 years) more borderline personality disorders (16%, 21/132 vs. 8%, 11/137,
χ2=3.27, df=1, P=.071) than older ones. Furthermore, patients living alone had a
personality disorder slightly more often (50%, 67/134 vs. 38%, 51/135, χ2=3.60, df=1,
P=.058) than married or cohabiting patients. All significant differences remained after
controlling possible confounding factors by logistic regression.
7.1.3.3  Inpatient and outpatient status   
Inpatients were more severely depressed (mean HAM-D score ±SD 24.9±5.0 vs. 18.4±5.4,
t=7.493; df=267, P<.001), had more often alcohol use disorders (39% vs. 22%, χ2=5.47,
df=1, P=.019), cluster B PDs (26% vs. 12%, χ2=4.94, df=1, P=.026), panic disorders with
agoraphobia (17% vs. 5%, χ2=6.34, df=1, P=.012), and melancholic (54% vs. 32%, χ2=7.12,
df=1, P=.008) and psychotic features (26% vs. 4%, Fisher’s exact test, df=1, P<.001) than
outpatients. These results remained significant after controlling for gender and age by
logistic regression.
7.1.3.4  Lifetime depressive episodes       
In logistic regression (LR) analyses controlled for age and gender, subjects with ≥ three
lifetime depressive episodes had a greater likelihood of personality disorders (OR 1.87,
95% CI 1.03-3.38, P=.026), and had pure MDD significantly less frequently than those with a
single episode (OR 0.36, 95% CI 0.16-0.80, P=.022) (I: Table 5).
7.1.3.5  Melancholic features (Study III)     
There were no significant differences in rates of any axis I and II comorbid disorders, or
in EPI neuroticism scores between melancholic and non-melancholic depression (III: Table
2). In order to control for the possible effect of severity the multivariate models were
used in the secondary analyses. In the LR models with melancholic features as the
dependent variable, the only significant finding was severity of depression (OR 1.10, 95%
CI 1.05-1.15, P<.001) when age, gender, severity of MDD, or either personality clusters or
neuroticism were simultaneously entered into the models as independent variables (III:
Table 3).
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7.2 Outcome of MDD (Study II)
7.2.1 Duration of the index episode
The median time with full MDE criteria after entry was only 1.5 (95% CI 1.3-1.7) months.
Altogether, 78% of the cohort achieved a symptom state below MDE criteria within three
months, 86% within six months, and 95% within 18 months (Fig. 3). The median time to full 
remission (lasting at least 2 consecutive months) was 8.1 (95% CI 5.2-11.0) months; 22% of
patients reached full remission within three months, 42% within six months, and altogether
only 63% within the 18-month follow-up (Fig. 4). The median duration of MDE before the
baseline interview was 3.5 (95% CI 2.9-4.1) months; including the prodromal phase, the
duration was 6.6 (95% CI 6.1-7.1) months.
7.2.2 Predictors of duration of the index episode
Significant predictors of time with full MDE criteria and of time to full remission were
very similar in the univariate analyses (Table 5).
Predictors for the final models were chosen on the basis of the primary hypothesis, but
their clinical and statistical validity and relevance (e.g. state vs. trait) were
considered before inclusion. Therefore, some self-reported scales scores (e.g. PSSS-R,
HS, and SSI) were not entered into the final multivariate analyses seeking independent
predictors (even though they might have been significant in univariate analyses). The
final Cox proportional hazards model was performed with age, gender, duration of MDE
before entry, number of prior MDEs and somatic disorders, melancholic and psychotic
subtypes of depression, personality and alcohol use disorders, mean BAI [anxiety symptoms]
and HAM-D scores [severity of depression], and size of social network simultaneously as
independent variables. After all non-significant findings were removed, severity of MDD
(OR 1.04, 95% CI 1.01-1.07, P=.004), longer duration of MDE prior to entry (OR 1.36, 95%
CI 1.02-1.81, P=.04) and personality disorder (OR 1.36, 95% CI 1.02-1.81, P=.04) predicted
time with full MDE criteria most significantly, while time to full remission was most
effectively predicted by severity of MDD (OR 1.03, 95% CI 1.00-1.07, P=.04) and anxiety
symptoms (OR 1.01, 95% CI 1.00-1.04, P=.01) (II: Table 3).
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7.2.3 Relapses and recurrences
Only 20 (10%) of the 198 patients who completed the 18-month interview had an immediate
relapse. Those with previous MDEs (OR 5.15, 95% CI 1.14-23.24, P=.03) and those aged ≥40
years (OR 3.19, 95% CI 1.01-10.11, P<.05) more often had relapses. The median length of
relapse during the follow-up was 2.2 months.
During the 18-month follow-up, 76 (38%) of the 198 patients had a recurrence (return of
symptoms sufficiently severe to satisfy criteria for an MDE after at least two consecutive
months of partial or full remission). The median time to the first relapse or recurrence
was 4.3 months (95% CI 2.93-5.67 calculated without time with full MDE criteria after
baseline), and the median length of recurrence was 1.5 months. The median score on the BDI
during relapses or recurrences was 19.0 (combined due to low numbers; only those with BDI
scores available [N=56] included). The BDI scores during the relapses/recurrences were
significantly lower than the respective patients’ scores at baseline (t=5.502, df=55,
P<.001).
In univariate LR analyses, several baseline factors predicted recurrence either
significantly or as a trend (Table 5). However, severity of MDD (OR 1.06, 95% CI
1.00-1.11, P=.04) and a higher number of comorbid psychiatric disorders (OR 1.25, 95% CI
1.03-1.51, P=.02) were the two most significant predictors in the backward stepwise
multivariate LR models, when age, gender, duration of MDE before entry, number of prior
MDEs, somatic disorders, comorbid psychiatric disorders, melancholic and psychotic
subtypes of depression, mean score on the HAM-D, size of social network, and the time at
risk for recurrence were entered as predictors. Partial remission from the index episode
was significantly associated with risk of recurrence during follow-up (OR 2.14, 95% CI
1.06-4.31, P=.03). However, when partial remission was added as a predictor in the
multivariate models, it did not remain significant after adjusting for the other
predictors, and was thus not included in the final multivariate models.
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Table 5. Univariate analyses of all possible predictors of time with full criteria, time
to full remission, and recurrences in the VDS    
____________________________________________________________________________________________________________________________
Predictors                          Time with full MDE criteria  a   Time  to full remission a    Recurrences b
(at entry)                          OR     95% CI         P          OR     95% CI         P      OR     95% CI         P
____________________________________________________________________________________________________________________________
Age,  yrs                           1.01   1.00-1.02      -          1.01   1.00-1.03      .073   1.00   0.98-1.03      -
Gender (male)                       0.97   0.71-1.33      -          0.83   0.56-1.24      -      0.92   0.47-1.78      -
Outpatient status                   0.90   0.62-1.29      -          1.05   0.65-1.70      -      0.78   0.34-1.76      -
Age at onset, yrs                   1.01   0.99-1.02      -          1.01   0.99-1.03      -      0.98   0.95-1.02      -
Longer MDE prior to entry           1.30   0.98-1.72      .069       1.30   0.91-1.84      -      1.78   0.97-3.26      .061
No. of previous episodes            1.02   0.97-1.08      -          1.03   0.96-1.10      -      1.12   0.98-1.28      .083
17-item HAM-D score                 1.03   1.01-1.06      .011       1.04   1.01-1.07      .013   1.07   1.01-1.03      .018
21-item BDI score                   1.03   1.01-1.05      .001       1.03   0.01-1.06      .006   1.05   1.01-1.09      .014
Beck Anxiety Inventory score        1.02   1.00-1.03      .015       1.03   1.01-1.04      .004   1.02   0.99-1.05      -
Beck Hopelessness Scale score       1.05   1.02-1.08      .003       1.05   1.01-1.09      .018   1.10   1.03-1.18      .006
Scale for Suicidal Ideation score   1.01   1.00-1.03      -          1.03   1.01-1.06      .010   1.06   1.02-1.11      .004
SOFAS score c                       1.02   1.00-1.03      .019       1.02   0.97-1.00      .076   1.01   0.98-1.04      -
Axis I comorbidity      
Dysthymia                           0.89   0.56-1.42      -          1.52   0.79-2.91      -      1.89   0.70-5.09      -
Anxiety disorders                   0.81   0.62-1.07      -          0.87   0.62-1.23      -      1.59   0.87-2.90      -
Alcohol use disorders               1.01   0.72-1.43      -          1.15   0.75-1.75      -      1.35   0.65-2.79      -
Axis II comorbidity    
Personality disorders               1.46   1.10-1.93      .008       1.44   1.01-2.05      .043   1.84   1.00-3.38      .049
    Cluster A                       1.47   1.01-2.15      .044       1.28   0.80-2.04      -      1.99   0.90-4.38      .089
    Cluster B                       1.24   0.83-1.85      -          1.12   0.68-1.85      -      2.27   0.94-5.48      .069
    Cluster C                       1.54   1.13-2.09      .006       1.79   1.20-2.68      .005   1.41   0.74-2.71      -
No. of psychiatric disorders        1.04   0.97-1.13      -          1.06   0.96-1.18      -      1.27   1.06-1.53      .009
Axis III comorbidity    
    No. of current somatic diseases 1.11   0.98-1.26      -          1.18   0.99-1.40      .071   1.05   0.82-1.36      -
    No. of all axis I-III disorders 1.06   0.99-1.14      .071       1.09   1.00-1.18      .051   1.19   1.03-1.38      .020
Psychotic MDD                       1.00   0.59-1.69      -          0.71   0.39-1.33      -      0.68   0.20-2.36      -
Psychosocial and personality factors  
Size of social network c            1.03   0.99-1.06      -          1.04   0.99-1.09      .093   0.98   0.90-1.07      -
PSSS-R score e                      1.02   1.01-1.03      <.001      1.02   1.00-1.03      .038   1.02   0.99-1.04      -
Negative life events d              1.00   0.97-1.03      -          1.02   0.98-1.06      -      1.02   0.95-1.09      -
Neuroticism e                       1.05   1.01-1.08      .016       1.05   1.01-1.10      .022   1.11   1.02-1.21      .020
____________________________________________________________________________________________________________________________
a
 Cox proportional hazards models; all analyses controlled for age and gender, risk reported for increasing time,
b
 Logistic regression models; all analyses controlled for age, gender, and time at risk for recurrence
c
 Scales reversed in order to improve comparability,
d
 Interview for Recent Life Events; objectively measured negative impact of adverse life-events,
e
 Eysenck Personality Inventory; dimension of neuroticism
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7.3 Stability and course of melancholic features (Study III)
7.3.1 Course of melancholic MDD
There were no statistically significant differences in the prospective course of
depression between the subtypes (III: Table 4). In the Cox proportional hazards models
adjusting for age and gender, time at full MDE criteria (OR 0.97, 95% CI 0.73-1.28, N.S.),
time to partial remission (OR 0.94, 95% CI 0.70-1.25, N.S.), time to full remission (OR
1.07, 95% CI 0.75-1.52, N.S.), time to first relapse/recurrence (OR 0.89, 95% CI
0.56-1.40, N.S.), number of relapses (12.2% v. 8.9%, χ2=0.55, N.S.), or recurrences (36.5%
v. 39.5%, χ2=0.18, N.S.) did not differ statistically significantly between melancholic
and non-melancholic depressives. Neither there were any significant differences in
duration of various symptom states (e.g. partial/full remission or MDE) analyzed by the
Mann-Whitney test. However, the retrospective duration of MDE before entry into the
cohort, with or without prodromal phase, was longer in non-melancholic than melancholic
depression (OR 1.37, 95% CI 1.06-1.78, P=.02 and OR 1.31, 95% CI 1.02-1.67, P=.04,
respectively).
7.3.2 Stability of melancholic features
Altogether, 32 (27%) of the 117 non-chronic non-melancholic patients and 23 (34%) of the
67 non-chronic melancholic patients who completed the 18-month interview were in a new
episode during the follow-up interviews. The original subtype of MDD persisted in 29 out
of 55 cases (53%), while in almost as many cases it changed (47%, 26/55): non-melancholic
MDD shifted to melancholic in eight out of 32 (25%) cases, and melancholic to
non-melancholic in 18 out of 23 (78%) cases (χ2=15.23, df=1, P<.001). Variation in
severity of episodes during the follow-up did not explain the changes of subtype. At six
months, 24% (13/55) of the depressed patients were melancholic, the proportion rising to
36% (16/45) at 18 months. There were no statistically significant differences in mean
HAM-D scores between the patients with and without melancholic features either at six or
18 months (mean=17.7, S.D. 6.8 v. mean=19.9 S.D. 4.9, t=1.312, df=40, N.S.; and mean=18.2
S.D. 5.9 v. mean=18.7 S.D. 4.5, t=0.217, df=27, N.S., respectively). The median HAM-D
score of the patients in a depressive episode at follow-up was 19.0 at both six and 18
months.
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7.4 Antidepressant and psychosocial treatments in MDD (Study IV)
7.4.1 Antidepressants   
7.4.1.1  Antidepressants received in the acute phase   
At baseline most patients (88%, 174/198) received antidepressants, and for the majority
(78%) the dosage level was adequate for the acute phase. More than half (57%, 112/198) of
the study cohort patients received SSRIs alone at baseline, about one fifth (18%, 36/198)
newer antidepressants (tetracyclics, NaSSA, SNRI, RIMA), only 8% (15/198) TCAs, and 6%
(11/198) combination treatment, usually SSRI and TCA. While SSRIs and newer
antidepressants were used inadequately in the acute phase in only about a tenth of cases
(7% and 11%, respectively), TCAs were used inadequately in about half (47%) (χ2=20.08,
df=2, P<.001). However, only a few, and none without remission, received augmentation of
pharmacotherapy (e.g. lithium or buspirone). Only 3% received ECT (Table 6).
7.4.1.2 Continuity of treatment    
In contrast to generally adequate treatment in the early acute phase, the continuity of
antidepressant treatment provision was far less complete, particularly in the continuation
and maintenance phases (Table 7, Figure 5). Although the median time on antidepressant
treatment was 55 (95% CI 34.7-75.3) weeks (Figure 5), premature termination of treatment
was common. In about half (49%, 86/174) of patients antidepressant treatment was
terminated before completion of a continuation phase, or in the early maintenance phase
for those with three lifetime episodes. One third of antidepressants were terminated in
the acute phase (33%, 57/174), i.e. while still in MDE or partial remission. About a
quarter (28%, 49/174) of patients completed a continuation phase lasting at least four
months. Only about a fifth (19%, 13/67) of those with three lifetime episodes proceeded to
a maintenance phase.
7.4.1.3 Predictors of premature termination          
In stepwise backward LR analyses with premature termination of antidepressant treatment as
a dependent variable, and factors significant in univariate analyses as independent
variables, premature termination was significantly predicted by no earlier antidepressant
treatment (OR 2.13, 95% CI 1.10-4.16, P=.026), and less severe depression (OR 1.58, 95% CI
1.00-1.13, P=.049). It also associated with negative treatment attitudes during the
follow-up: 86% (18/21) of the patients with negative attitudes at six months, and 74%
(20/27) at 18 months had premature termination of antidepressant treatment.
55
Table 6. Treatments received, and the highest level of remission achieved from the index   
episode of the VDS MDD patients followed for 18 months       
____________________________________________________________________________________________________________________________
Variables                           Full  remission     Partial  remission   MDD                Total           
                                    (N=122)             (N=61)               (N=15)             (N=198)     
                                    N     (%)           N      (%)           N      (%)         N      (%)        χ2/F     P
____________________________________________________________________________________________________________________________
Antidepressant treatment   
Antidepressant at baseline        101    (83)          58    (95)           15    (100)         174    (88)         8.01     .018
Adequacy at first
antidepressant trial: a
   Adequate                        86    (71)          53    (87)           15    (100)         154    (78)        11.79     .019
   Inadequate                      15    (12)           5     (8)            -     (-)           20    (10)                       
   No antidepressant               21    (17)           3     (5)            -     (-)           24    (12)                       
≥ 3 trials on antidepressants      13    (20)          13    (36)           10    (71)           38    (31)        14.70     .001
Antidepressant combination
treatment                          17    (14)          12    (20)            5    (33)           34    (17)                  -
Buspirone augmentation              7     (6)           4     (7)            -     (-)           11     (6)                  -
Lithium augmentation                -     (-)           -     (-)            -     (-)            -     (-)                  -
Psychosocial treatments    
Psychotherapeutic support         119    (98)          60    (98)           15    (100)         194    (98)                  -
Psychotherapy                      20    (16)          11    (18)            -     (-)           31    (16)                  -
All psychotherapeutic
sessions, No, mean (SD) b          16.9  (15.7)        24.6  (26.6)         38.3  (17.6)         21.1  (20.7)       9.13     <.001
Duration of psychotherapeutic
treatment, months, mean (SD) c      9.4   (6.5)        11.5   (6.0)         17.5   (3.6)         10.7   (6.5)      11.93     <.001
Visits to psychiatrist,
mean (SD) d                         2.9   (3.0)         5.3   (5.9)          8.6   (4.5)          4.1   (4.5)      29.69     <.001
ECT                                  1      (1)          3      (5)           1      (7)           5      (3)                 -
____________________________________________________________________________________________________________________________
a
 Antidepressant/s at adequate dosage level for at least four weeks in acute phase,
b
 Data missing for 4.0% of patients, N=190, c Data missing for 3.5% of patients; N=191; d Kruskal Wallis test
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Table 7. Continuity of antidepressant treatment in the index episode and lifetime number 
of MDEs among the VDS patients followed for 18 months    
____________________________________________________________________________________________________________________________
Variables                           Single episode    2 episodes      ≥ 3 episodes      Total     
                                    N=66              N=65            N=67              N=198     
                                    N      %          N      %        N      %          N      %         χ2       P
____________________________________________________________________________________________________________________________
No antidepressant (baseline)       16    (24)         2     (3)         6     (9)        24     (12)     14.73    .001
Antidepressant (baseline)          50    (76)        63    (97)        61    (91)       174     (88)
Antidepressants ongoing
for the index episode:             15    (23)        26    (40)        35    (52)        76     (38)      8.60    .014
    In acute phase                  8    (12)        14    (22)        21    (31)        40     (20)              -
    In continuation phase           1     (2)         1     (2)         1     (2)         5      (3)              -
    In maintenance phase            6     (9)        11    (17)        13    (19)        31     (16)              -
Antidepressants discontinued:      35    (53)        37    (57)        26    (39)        98     (49)      8.60    .014
In MDE                              4     (6)         6     (9)         5     (7)        15      (8)              -
In partial remission               17    (26)        17    (26)         8    (12)        42     (21)              -
In continuation phase               7    (11)         9    (14)         7    (10)        23     (12)              -
In maintenance phase                7    (11)         5     (8)         6     (9)        18      (9)              -
Antidepressant discontinued
and restarted                       6     (9)         6     (9)         7    (10)        19     (10)              -
____________________________________________________________________________________________________________________________
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7.4.1.6 Self-reported antidepressant adherence          
The majority of patients (77%, 109/142) reported taking antidepressants regularly when
treatment was ongoing, about a tenth (11%, 16/142) somewhat irregularly, and a similar
proportion (12%, 17/142) very irregularly or never. Of 142 patients interviewed, 29 (20%)
reported non-adherence at both follow-ups. In stepwise backward LR models adjusting for
age, gender, and severity of MDD, having no avoidant personality (OR 4.83, 95% CI
1.33-17.48, P=.017), or no anxiety disorder (OR 2.40, 95% CI 1.01-5.71, P=.047) persisted
significant predictors for continued non-adherence. Two-thirds (60%, 74/124) of patients
with no ongoing psychiatric treatment, and almost all (92%, 68/74) of those who had
remained in treatment answered questions about adherence at 18 months.
7.4.2 Psychosocial treatments      
7.4.2.1 Treatments received in the acute phase   
Nearly all patients (98%) received psychotherapeutic support in the early acute phase, but
only a few, and none without remission, had weekly psychotherapy (16%) (Table 6).
7.4.2.2 Continuity of psychosocial treatments    
Not unexpectedly, patients with poorer outcome received psychosocial treatment for longer
(Table 6). However, only two thirds (58%, 44/76) of the patients without full remission
remained in psychiatric care, and a third of them (32%, 24/76) were without any follow-up
treatment at 18 months. Most patients were already receiving psychosocial support at
baseline, but weekly psychotherapy began about three months later (mean±SD 2.9±4.0
months), and lasted for about one year (mean±SD 11.0±6.0 months).
In stepwise backward LR analyses with receiving weekly psychotherapy as a dependent
variable, the most significant predictors for having psychotherapy were fewer DSM-IV
current comorbid psychiatric disorders (OR 1.37, 95% CI 1.02-1.82, P=.034), larger social
network (OR 1.12, 95% CI 1.00-1.25, P=.046), and more severe suicidality (OR 1.08, 95% CI
1.02-1.14, P=.004). Moreover, patients with personality disorder had psychotherapy more
infrequently than those without personality disorder (9%, 8/85 vs. 20%, 23/113, χ2=4.40,
df=1, P=.036). This result remained significant (OR=2.88, 95% CI 1.11-7.44, P=.029) when
entered simultaneously with age, gender, and other significant factors like size of
social network, neuroticism, and more severe suicidality into stepwise backward LR models.
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7.4.2.3 Self-reported psychosocial treatment adherence        
Nearly all patients (92%, 68/74) still in psychiatric care, and about two thirds (56%,
69/124) of those without ongoing treatment, answered questions about adherence at 18
months. Nearly all who had received weekly psychotherapy (96%, 27/28) reported attending
sessions regularly. Most patients (75%, 82/109) with psychotherapeutic support also
reported attending sessions regularly, about a fifth (17%) somewhat irregularly, and 7%
very irregularly or never.
7.4.3 Attitudes towards treatments
At baseline, the majority (85%, 223/262), and two-thirds (61%, 164/268) of patients,
respectively, had positive attitudes towards psychosocial and antidepressant treatments.
Among study cohort patients, attitudes towards psychosocial treatments remained positive,
and in most (82%, 56/68) cases negative attitudes towards antidepressants became positive
during the follow-up. The factors explaining negative attitudes towards antidepressants at
baseline were younger age (OR 1.03, 95% CI 1.00-1.05, P=.031), lower score on BAI (OR
1.04, 95 % CI 1.01-1.07, P=.019) and HAM-D (OR 1.08, 95% CI 1.03-1.14, P=.003), longer
duration of MDE (OR 1.05, 95 % CI 1.00-1.10, P=.050), and having no current alcohol use
disorder (OR 2.00, 95% CI 1.00-3.99, P=.050), while the factors explaining negative
attitudes about psychosocial treatment were male gender (OR 4.25, 95% CI 1.84-9.80,
P=.001) and dysthymia (OR 3.22, 95% CI 1.22-8.48, P=.018) (IV: Table 3).
Among those with reservations/negative attitudes about antidepressants the most frequently
reported reasons for these attitudes were fears of dependence and side-effects, which were
reported by nearly half of the patients (43% and 41%, respectively) at baseline. No belief
in getting any help from the treatment (43%), and unwillingness to confide in a stranger
(33%) were the most frequently reported reasons for negative attitudes towards
psychotherapeutic treatments. Patients with negative attitudes about antidepressants at
entry tended to terminate them in the acute phase more often (43%, 22/51 vs. 29%, 34/119,
df=1, χ2=3.43, P=.064). Those with negative attitudes to antidepressants or psychosocial
treatments at 18 months also reported non-adherence to them more often (79%, 19/24 vs.
20%, 26/130, χ2=34.29, df=1, P<.001, and 75%, 6/8 vs. 24%, 33/140, χ2=10.31, df=1, P=.001,
respectively).
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8. DISCUSSION
8.1 Main findings
A typical psychiatric  patient  with  MDD in psychiatric  care suffered from  many  comorbid
disorders; over half had current comorbid anxiety disorders (57%), nearly half personality
disorders (44%), and a quarter alcohol use disorders (25%). Only one fifth (21%) had pure
depression without any comorbid disorder.
Achieving full remission took about eight months, so despite the use of new
antidepressants the outcome of MDD appears not to be improved in psychiatric care.
Although patients typically responded early to the treatment (most in 4-8 weeks), the
major problem was the long period with only partial remission. In addition, about 40% of
the patients had a recurrence of MDD during the 18 months of follow-up. Numerous factors
predicted the duration of MDE to some extent, but more severe depression and presence of
current comorbidity were the two most robust predictors. More severe depression was also a
significant predictor of recurrence. There were no major differences in current
comorbidity or course of depression between melancholic and non-melancholic patients.
Moreover, the consistency of DSM-IV melancholic features across episodes appeared weak.
Most depressive patients in psychiatric care received adequate antidepressant (88%) and
psychotherapeutic treatments (98%) in the early acute phase, and had favourable attitudes
towards them. Nevertheless, over time antidepressants were terminated too early in about
half of the patients, often following their autonomous decision. About a third of the
patients not achieving full remission were without any psychosocial treatment by the end
of follow-up. Negative treatment attitudes were more common towards antidepressants than
psychosocial treatments, and tended to predict premature termination. The main challenge
in psychiatric care appears to be continuity of treatments.
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8.2 Methods
8.2.1 Representativeness of the cohort sample
Clinical studies conducted on representative unselected samples of commonly met, highly
comorbid, depressive patients are extremely sparse. However, the familiar tendency for
patients to have undergone many prior treatments in studies conducted in tertiary-level
treatment centres may produce bias towards more chronic, severe and recurrent illnesses
compared with more unselected cohorts of MDD patients (Spijker et al., 2002; Furukawa et
al., 2000; Roy-Byrne et al., 2000). Moreover, the most influential outcome studies were
undertaken during the past era of tricyclic antidepressants and before the recommendation
of continuation and maintenance treatments. In addition, only a few recent psychiatric
care studies have reported how treatments, especially after the immediate acute phase, are
carried out, and which factors predict treatment inadequacy, premature termination and
non-adherence among depressive patients (Ramana et al., 1999; Sirey et al., 1999; Simon et
al., 2001; Cuffel et al., 2003; Kennedy et al., 2003).
The present naturalistic study (I-IV) involved a relatively large (N=269) cohort of both
outpatients and inpatients with MDD, effectively representing psychiatric patients with a
new episode of MDD in the city of Vantaa; and it took place during the era of modern
antidepressants in 1997-1999 in a community psychiatric setting. On the basis of an
epidemiological survey, two thirds of all depressed subjects in the general population of
Vantaa seeking treatment from psychiatrists are treated in the PMCD (Rytsälä et al.,
2001).
8.2.2 Study refusals and drop outs
The rate of drop-outs from the main follow-ups was quite low, as 87% of the cases could be
interviewed at least once after baseline. The patients whose diagnosis switched to bipolar
I or II disorder during the 18-month follow-up (5%) were excluded from the analyses. As
the factors associating with dropping out included both positive (younger age) and
negative (living alone, neuroticism, dysthymia) outcome predictors, the small percentage
of drop-outs is unlikely to have biased findings. In some analyses, however, only those
who completed the whole 18-month follow-up could be included. In these cases, the rate of
drop-outs was 23% (N=58; including eight patients who died during the follow-up), which
is likely to have somewhat biased findings towards better adherence to treatments (Study
IV).
62
8.2.3 Diagnostic measures
The patients were diagnosed using semi-structured interviews with excellent reliability
(kappa=0.86) for the diagnosis of MDD. However, the reliability of comorbid disorder and
melancholic MDD diagnoses is unknown, and the distinction between melancholic and
non-melancholic depression was based solely on the SCAN-interview and DSM-IV criteria.
Moreover, diagnoses of axis III disorders were based on self-report, although only
diseases diagnosed by a physician were included.
Axis II diagnosis were assessed using the semi-structured SCID-II interview for DSM-III-R,
as the SCID II for DSM-IV was not yet available in February 1997. Differences between
DSM-III-R and DSM-IV were taken into account by excluding masochistic PD. Passive-
aggressive PD was included because it belongs to the personality disorder NOS in DSM-IV.
Patients were also interviewed with the SCID-II during their depression, which may (Stuart
et al., 1992; Peselow et al., 1994; Ferro et al., 1998), or may not (Loranger et al.,
1991) have inflated the prevalence of personality disorders. This, as well as the
inclusion of patients with current alcohol use disorders, was done deliberately in order
to investigate the persistence and effects of these disorders in the follow-up. Patients
with eating disorders and those who have experienced acute psychological traumas are
probably underrepresented in the VDS. Only 4% of the patients admitted to occasional
misuse of sedatives, or use of illicit drugs.
8.2.4 Life-chart and definitions for outcome
Many approaches to the longitudinal measurement of psychopathology have been developed.
Probably one of the most influential measurements is the Longitudinal Interval Follow-up
Evaluation (LIFE) methodology, first used to investigate the outcome of depression in the
NIMH-CDS (Keller et al., 1987). The LIFE is a semi-structured interview and rating system
for assessing the longitudinal course of psychiatric disorders in sufficient detail to
provide the basis for calculating length of episodes and time to remission (Keller et al.,
1987). In the VDS the outcome of MDD was investigated by using a graphic life chart, which
is similar, but not identical, to the LIFE. As is done with the LIFE, change points in the
psychopathologic state were inquired about using probes related to important events.
Moreover, all patient records and monthly BDI-ratings (for the first 6 months) were
available. Unlike the LIFE, patients’ follow-up time was classified into periods of DSM-IV
MDE, or partial (1-4 criteria symptoms) or full (no symptoms) remission. The major
advantage of this classification is that it counts episodes and defines recurrences
precisely, as does any clinician when using the DSM-IV.
However, comparison of the findings with studies using the LIFE can be undertaken only
with some caution. For example, it appears that criteria for full remission in the VDS
were more stringent than those used for recovery in the CDS (Psychiatric Status Ratings,
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1-2; no symptoms or 1 to 2 symptoms to a mild degree). The mean±SD HAM-D scores at the
18-month interview were 2.7±2.8 for those with full remission, 8.3±4.3 for those with
partial remission, and 18.5±4.8 for those with an MDE. In practice, if those with only one
or two symptoms were also included in the full remission grouping, 76% of patients would
have a recovery (instead of 63%); this percentage is comparable with the number of
patients fully recovered in the CDS within two years (81%) (Keller et al., 1992).
Unfortunately, there is currently no universally accepted definition of remission (Keller,
2003), despite significant efforts (Frank et al., 1991). Nevertheless, in most
longitudinal studies, recurrence/relapse follows a period of remission, which is
relatively consistently defined as the presence of only one or two minimal symptoms of
major depression to a mild degree, or complete absence of symptoms for at least two months
(Keller, 2003). So, having used the same criteria for duration for remission, it is likely
that the findings from the VDS are comparable to other studies.
8.3 Current comorbidity of psychiatric disorders in MDD (Study I)
When presenting for treatment for a new depressive episode, a typical psychiatric patient
with MDD suffered from one to three comorbid axis I or II disorders; only one fifth had
pure depression without any comorbid disorder. As expected, comorbid disorders also varied
markedly by a number of relevant background factors, such as gender, in- vs. outpatient
status, type of residential area, and somewhat by lifetime number of depressive episodes.
Current comorbidity in MDD was extremely common; anxiety disorders were prevalent in 57%,
alcohol use disorders in 25%, and personality disorders in 44%, which is more in line than
expected with earlier, mostly tertiary level studies (Van Valkenburg et al., 1984; Kocsis
et al., 1986; Alnaes & Torgersen, 1988; Coryell et al., 1988; Sanderson et al., 1990;
Stuart et al., 1992; Flick et al., 1993; Grunhaus et al., 1994; Golomb et al., 1995b;
Pepper et al., 1995; Sato et al., 1996; Alpert et al., 1997; Pini et al., 1997; Schatzberg
et al., 1998; Fava et al., 2000; Zimmerman et al., 2000; McDermut et al., 2001). However,
when considering the representativeness of the VDS cohort, and the fact that all comorbid
patients with MDD were deliberately included, this finding is less surprising.
Current comorbidty in MDD was also highly concentrated; anxiety and personality disorders
were commonly complicated by current alcohol abuse or dependence, particularly among
subjects with cluster B PD. Moreover, social phobia, specific phobia and agoraphobia
without panic disorder in cluster C PDs, and panic disorder in cluster B PDs, were
frequently found. These findings accord with the studies reporting high prevalence of
comorbid anxiety disorders in borderline PD (Zanari et al., 1998; Zimmerman & Mattia,
1999), cluster B or C PDs (Oldham et al., 1995), different axis I disorders (Alnaes &
Torgersen, 1988; McGlashan et al., 2000), or in MDD (Alpert et al., 1997).
64
Comorbidity varied by gender, in-vs. outpatient status, type of residential area, and
somewhat by lifetime number of depressive episodes. Not surprisingly, males had twice the
prevalence of current alcohol use disorders as females (39% vs. 19%), which is consistent
with a study (Fava et al., 1996a) reporting more lifetime alcohol use disorders among
males. One crucial neglected area of research has been the difference in clinical features
between in- and outpatients. Inpatients not only had more severe and more common
melancholic or psychotic depression than outpatients, but also a higher prevalence of
alcohol use disorders (39% vs. 22%), cluster B personality disorders (26% vs. 12%), and
panic disorder with agoraphobia (17% vs. 5%). It was also found that the more recurrent
the depression, the lower the prevalence of pure MDD. This accords with earlier
prospective outcome studies reporting a negative impact of multiple disorders on MDD
outcome (Keller et al., 1984; Sargeant et al., 1990; Coryell et al., 1992; Mueller et al.,
1994; Paykel et al., 1995; Alnaes & Torgersen, 1997).
The catchment area in the VDS was divided into East and West-Vantaa, based on the
established service areas in Vantaa healthcare. East-Vantaa includes some socio-
economically disadvantaged areas, and overall has about 10% lower average per-capita
income, 25% higher unemployment, 20% fewer university graduates, and 40% more persons
from ethnical minorities than West-Vantaa. On the basis of clinical experience within the
community health care system, higher rates of alcohol use and personality disorders among
MDD patients living in the more socioeconomically disadvantaged areas of East Vantaa were
expected. Markedly higher PD prevalences and a somewhat less striking trend of heavy
drinking in the East were indeed found. This suggests that current comorbidity of MDD may
vary even by the type of residential area.
8.4 Outcome of MDD (Study II)
The duration of the index episode in our representative secondary-level cohort,
comprising predominantly (85%) outpatients, was no shorter than in previous studies
despite more extensive (88%) and more adequate use of the new antidepressants in the acute
phase. This finding contrasts with results from a Japanese sample (Furukawa et al., 2000),
but accords with a more recent tertiary-level long-term outcome study (Kennedy et al.,
2003). Surprisingly, no differences between outpatients and inpatients regarding length of
the MDE or rates of recurrence were found.
The rates of remission from the index episode in the VDS were comparable with those
reported in older studies. Within three months, 22% of our cohort reached full remission,
versus 41% (Keller et al., 1992), 30% (Myers et al., 2002) and 33% (Ramana et al., 1995)
in other studies. The same percentages for full remission within six months were 42% in
the VDS versus 54% (Keller et al., 1992), 50% (Ramana et al., 1995) and 43% (Kennedy et
al., 2003) in other studies. However, only two-thirds (63%) of the patients reached
strictly defined full remission within 18 months, taking a relatively long median time of
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eight months. Although patients typically responded early to treatment, the major problem
was the long period with only partial remission, which is partly explained by the strict
definition of full remission used. Also, unlike other studies (Ramana et al., 1995; Myers
et al., 2002), all comorbid patients with MDD were deliberately included in the VDS. When
all the subjects with a concurrent major psychiatric or physical illness (Ramana et al.,
1995; Myers et al., 2002) were excluded from the data, the median time to full remission
somewhat decreased (from 8.1 to 7.2 months). Thus, a representative psychiatric cohort of
MDD patients who typically have multiple current comorbid disorders may also include
subjects with many known risk factors for poor outcome of MDD.
More severe depression, and longer duration of MDE before entry were found to predict
longer episode, in line with earlier prospective studies (Keller et al., 1982; 1984; 1992;
Sargeant et al., 1990; Wells et al., 1992; Ramana et al., 1995; Mueller et al., 1999;
Parker et al., 2000b; Myers et al., 2002). However, it was somewhat unexpected to find
that severe MDD was such a robust predictor among all other theoretically relevant risk
factors. The finding that anxiety symptoms and personality disorders associated with
longer duration of depression accords with earlier studies investigating the effects of
either comorbid anxiety (Coryell et al., 1988; 1992; Clayton et al., 1991) or personality
disorders (Sato et al., 1993; Greenberg et al., 1995; Ilardi et al., 1997; Viinamäki et
al., 2002; 2003) on the outcome of MDD.
Social support, as objectively measured by the size of the social network at entry and by
the negative impact of preceding adverse life-events, had little or no effect on time to
remission, which accords with some earlier studies (Andrew et al., 1993; Paykel et al.,
1996). In contrast, social support as subjectively perceived was strongly related to the
duration of depression. Subjectively perceived social support and neuroticism, however,
were strongly correlated with the level of depressive symptoms or presence of comorbid
personality disorders and were therefore not included in the final multivariate models. No
association between adequacy of pharmacotherapy in the early acute phase and episode
duration was found, probably due to homogeneity in the amount and adequacy of the
treatment received, and possibly because of the known tendency for sicker patients to
receive more treatment in a naturalistic study (Sturm, 1999).
The recurrent nature of depression is one of its fundamental features, and has major
treatment implications. During the follow-up, about 40% of patients suffered a
recurrence, which is consistent with the rates reported in speciality settings (Keller et
al., 1983; Ramana et al., 1995; Keller & Boland, 1998; Mueller et al., 1999; Kennedy et
al., 2003). However, it seems that although the rate of recurrence in the VDS was similar
to older studies, the episodes during the follow-up were milder and shorter (Solomon et
al., 1997). In this respect, findings from the VDS support those from a Japanese sample
(Furukawa et al., 2000) in which the index episode duration was calculated to be 25% - 50%
shorter than in older literature. The findings that number of prior MDEs, older age,
longer duration of MDE before entry, personality disorders or neuroticism, hopelessness,
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and achieving only partial remission from the index episode are associated with the risk
of relapse/recurrence are convergent with previous studies (Keller et al., 1982; 1983;
Coryell et al., 1991; Maj et al., 1992; Surtees & Barkley, 1994; Ramana et al., 1995;
Alnaes & Torgersen, 1997; Ilardi et al., 1997; Keller & Boland, 1998; Lin et al., 1998;
Mueller et al., 1999). Partial remission as a predictor in the multivariate models did
not remain significant, which supports the interpretation of partial remission as an
intermediate symptom state that is effectively predicted by more important predictors of
outcome. The rate of recurrence ranged from 27% among those with a mild index episode to
58% among those with a severe one, and from 31% among those with no comorbid disorder to
54% among those with three or more current comorbid psychiatric disorders. Thus, severe
depression and high number of comorbid disorders appear to be the major factors
influencing the medium-term risk of recurrence.
Severity of MDE was found to be strongly associated with the risk of recurrence in
medium-term follow-up. In previous studies severity of depression has either predicted
recurrences (Ramana et al., 1995) or not (Keller et al., 1983; Sherrington et al., 2001).
In studies (Keller et al., 1983; Sherrington et al., 2001) that found no association
between severity and recurrences, most subjects were inpatients with severe and recurrent
melancholic depression. However, severity of depression also predicted recurrence in the
study by Ramana et al. (1995), in which the clinical severity of MDD varied from mild to
severe, and the proportion of patients with melancholic features - as in our study (36%) -
was somewhat lower (63%). So, it appears that at least in cohorts of less melancholic MDD
outpatients with less severe depression in medium-term follow-up, the severity of
depression might be a more useful predictor of recurrence than the number of prior MDEs.
8.5 Stability and course of melancholic features (Study III)
The hypothesis that the prevalence of current comorbidity of axis II disorders and
neuroticism would be higher among the non-melancholic patients was tested, and found not
to be the case. The finding of no significant differences in rates of axis II disorders or
neuroticism between melancholic and non-melancholic patients is consistent with some
earlier studies (Zimmerman et al., 1986 [RDC criteria]; Shea et al., 1987; Tedlow et al.,
2002), including a recent entirely outpatient study (Tedlow et al., 2002) with about the
same prevalence of melancholic patients (39%) as in the VDS (36%). However, it is
discordant with most of the studies on inpatients (Charney et al., 1981; Davidson et al.
1985; Zimmerman et al., 1986 [DSM-III-R criteria]; Parker et al., 1998), or non-clinical
populations (Kendler et al., 1997). Nevertheless, some methodological disparities between
studies need to be considered. Patients were interviewed with the SCID-II during their
depression, and, unlike many other studies, alcohol use disorders and serious suicide risk
were not exclusions in the VDS, which probably led to the higher prevalences of
personality disorders. Because melancholic patients had a clinically more severe index
episode than non-melancholic patients, the effect of severity was controlled for in the
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multivariate models. However, the finding that DSM-IV melancholia was not associated with
lower rates of personality disorders, or any personality disorder cluster, replicated the
result of Tedlow and colleagues (2002), who also used semi/structured interviews for both
MDD and comorbid personality disorders, and controlled for the effects of additional
comorbid disorders and age. It is also noteworthy that psychotic features in the VDS
population only moderately clustered in the melancholic depression group, thus not
strongly supporting the hierarchical model of Parker (2000).
Also tested was the hypothesis that episode subtype would be consistent for the subsequent
episodes, and again this was not the case. The results indicate a low level of subtype
stability for subsequent episodes, which in fact is highly consistent with most earlier
studies (Kendell, 1974; Paykel et al., 1976; Young et al., 1987), including a very recent
one reporting not only instability of subtypes but also instability of symptoms in MDD
(Oquendo et al., 2004). Instability of subtypes did not reflect differences in the
severity of episodes during follow-up, although after the index episode the recurrent
episodes were milder and shorter in this study, probably due to the treatment received.
Despite the lack of difference in symptom severity between melancholic and non-
melancholic episodes during the follow-up phase, the theoretical possibility that the
treatment received benefited melancholic more than non-melancholic episodes, perhaps
resulting in relatively fewer melancholic recurrences and therefore lower consistency
across episodes, cannot be excluded. In order to explore the possibility that presence of
psychomotor symptoms might better differentiate between the postulated subtypes, the data
were reanalyzed by dichotomizing the patients according to presence or absence of
psychomotor symptoms. Consistent with the presented findings, no significant subgroup
differences emerged. Nevertheless, these findings have to be treated with caution due to
the limited number of new episodes, the only medium-term follow-up, and the fact that the
CORE measure (Parker et al., 1994; Parker & Hadzi-Pavlovic, 1996) for psychomotor
symptoms was not used. Moreover, the possibility cannot be excluded that using a more
sophisticated measure of psychomotor symptoms such as CORE (Parker et al., 1994; Parker &
Hadzi-Pavlovic, 1996) would have produced different findings.
When comparing the course of depression in melancholic and non-melancholic MDD, no
differences in prospective course between the subtypes were found. The duration of index
episode, time to first subsequent MDE, number of recurrences/relapses, and duration of
different symptom states did not significantly distinguish melancholic and non-melancholic
depression. This finding is consistent with most earlier inpatient studies reporting no
differences in outcome between melancholic and non-melancholic depression (Keller et al.,
1984; 1986; Kiloh et al., 1988; Parker et al., 1992; Paykel et al., 1995; Brodaty et al.,
2001; Kennedy et al., 2003), but not all (Lee & Murray, 1988; Duggan et al., 1991). The
retrospective finding that melancholic patients had MDE of shorter duration prior to
baseline seems to be explained by the factors associating with treatment facilities.
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Melancholic patients with more severe depressive symptoms and lower functional capacity
appear to be more easily recognized by primary care and occupational health services than
non-melancholic patients, and thus more promptly referred to secondary level psychiatric
care.
8.6 Antidepressant and psychosocial treatment in MDD (Study IV)
In contrast to the generally adequate treatment in the early acute phase, continuity of
antidepressant treatment was far less complete in the later acute, continuation and
maintenance phases. About half (49%) of the patients terminated antidepressant treatment
prematurely, and only about a quarter (28%) completed a continuation phase of at least
four months. Patients with less severe depression and those without previous
antidepressant treatment were more likely to terminate medication prematurely. Those who
did so while still in the acute phase achieved full remission significantly less often
(42% vs. 66%), and in a longer time than other patients.
Premature termination of antidepressants was predicted by negative attitudes at entry.
Underlying these attitudes most frequently were fears of dependence (43%) or side-effects
(41%). Many depressive patients also reported having taken an active, autonomous role in
the decision to terminate antidepressants. "Patient’s autonomous decision" was a more
common reason than all perceived side-effects of antidepressants, poor response or
subjectively perceived recovery. These results accord with findings in the population of
the UK Defeat Depression campaign (Paykel et al., 1998) as well as with other recent
studies, which reported factors such as stigma, health-beliefs, and negative attitudes to
be important risk factors for non-adherence (Melfi et al., 1998; Demyttenaere & Haddad,
2000; Demyttenaere et al., 2001; 2003; Sirey et al., 2001; Keller et al., 2002; Lingam &
Scott, 2002; Lin et al., 2003).
Continuity of psychotherapeutic treatments was associated with more severe and more
prolonged depressive symptoms. Noteworthy, however, was the finding that about a third
(32%) of the patients not achieving full remission during the follow-up were without any
psychosocial treatment at 18 months. Less than a fifth (16%) of the patients received
weekly psychotherapy during the follow-up, which was somewhat surprising because about
third (34%) of the attending professionals in the PMCD were qualified and certified
therapists in specific psychotherapy, and the mean number of sessions was high enough for
brief psychotherapy. The patients who received psychotherapy were either those able to
form a good treatment alliance, and thus probably more able to benefit from therapy, or
suicidal patients who needed more intensive treatment in the acute phase and also received
it more promptly. Despite recommendations in practice guidelines (Schulberg et al., 1998;
Anderson et al., 2000; APA, 2000; Bauer et al., 2002; Suomen Psykiatriyhdistys, 2004) for
more intensive treatment, patients with personality disorders were the least likely to
receive weekly psychotherapy.
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Negative treatment attitudes at baseline were more common towards antidepressants than
psychotherapeutic treatments, but in most (82%) cases these attitudes became positive
during the treatment. The fact that MDD patients with negative attitudes were not those
with comorbid personality or alcohol use disorder did not support the primary hypothesis.
On the contrary, patients with alcohol use disorders had more positive attitudes towards
antidepressants. Men and MDD patients with dysthymia (double depression) needed more
encouragement before accepting psychotherapeutic treatments. The main reasons given for
negative attitudes about psychosocial treatments were unwillingness to confide in a
stranger, and patients believing they would not be helped by the treatment. Younger age,
less severe and longer-lasting depression, and milder anxiety symptoms also associated
with negative treatment attitudes.
Non-adherence is rarely an "on-off" phenomenon. Treatments may occur more or less
irregularly, and it may be unclear whether this significantly affects achieving treatment
goals or not. In contrast to the hypotheses, those with continued self-reported non-
adherence to antidepressants were more often those without comorbidity, expecially if they
were without anxiety and avoidant personality disorders. So it seems that presence of
perceived distress is also a major factor that motivates continuation with treatment.
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9. CONCLUSIONS AND FUTURE IMPLICATIONS
9.1. Conclusions
The recognition of comorbidity has important clinical significance in psychiatric care.
Comorbidity of MDD is not only highly prevalent, but often also multiple and concentrated.
It appears to predict a longer duration of MDE, and is associated with greater risk of
recurrence.
The outcome of MDD appears not to be improved in psychiatric care. Achieving full
remission takes a relatively long time, and although patients typically respond early to
treatment, the major problem is the long period with only partial remission. Moreover, the
rate of recurrence seems to be high. Severity of MDE and comorbidity are the two most
significant predictors for the duration of MDE and risk of recurrence.
The descriptive validity of the DSM-IV melancholic features specifier may be questionable
in MDD. There appear to be no major differences in current comorbidity or course of
depression between melancholic and non-melancholic patients. Also, the consistency of
DSM-IV melancholic features across episodes appears weak.
Problems of psychiatric care in MDD are mostly related to continuity of treatment. Many
depressive patients take an active, autonomous role in the decision to terminate
antidepressants. Premature termination not only associates with patients’ negative
attitudes, and fears of addiction and side-effects, but also appears to reflect their
willingness or demands to cope without medicine. Negative treatment attitudes seem to be
more common towards antidepressants than psychotherapeutic treatments, but these attitudes
tend to become positive during the treatment. Less than a fifth of MDD patients receive
weekly psychotherapy in psychiatric care. This is somewhat surprising, because quite a
large proportion of professionals are qualified and certified therapists in specific
psychotherapy, and the number of sessions is high enough for brief, focused psychotherapy.
Patients with personality disorders appear to be very unlikely to receive weekly
psychotherapy.
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9.2 Clinical implications
It is likely that greater diagnostic precision, and better recognition of comorbid
disorders will improve depression outcome. More complete and accurate diagnostic practice
may serve as a better predictor of course and outcome, and may impact on patients’
satisfaction with treatment, their alliance with treating professionals, selection of
medication, and recommendation for psychotherapy. Comprehensive diagnostic evaluation also
provides essential information to patients. It is always important to consider the effect
of comorbidity on the outcome when interpreting findings from naturalistic outcome
studies, as well as in planning and operating treatment facilities for psychiatric
patients with MDD.
Severity of depression should influence clinical decision-making regarding the need for
maintenance therapy, particularly among patients who are having their first or second MDE,
when maintenance therapy is not usually recommended. Use of observer / self-report scales
measuring severity of depression are recommended for routine clinical practice.
Providing psychoeducation to all depressive patients (and their families) seems essential.
Psychoeducation should include information on antidepressants - not only their
side-effects but also their non-addictiveness, and mechanisms of action. This might prove
an effective way to improve continuity of treatments and outcome of depression. Moreover,
it is important to motivate patients at least to try antidepressants, and to regularly ask
about their treatment attitudes in order to recognize those at risk of non-adherence.
Depression also seems to be pleomorphic in its manifestations across episodes. Considering
treatment, instability of the MDD subtype across subsequent episodes suggests that the
medication used in previous episodes is not necessarily always optimal in a recurrence.
From secondary and tertiary preventive perspectives, improving the continuity of treatment
appears a crucial task for improving the outcome of psychiatric patients with MDD.
Providing specific psychotherapies more often in psychiatric care, especially for MDD
patients with personality disorders, could also enchance the quality of care.
Both professionals and patients face difficulties in complying with treatment guidelines,
and the treatment eventually provided is the result of their interaction and compromises.
Despite the unquestionably important role of practice guidelines in psychiatric care,
clinicians should also keep in mind that evidence-based information on treatments in
common, highly comorbid MDD patients is still lacking. While awaiting further studies to
provide this information, the challenges in psychiatric care include providing better and
more comprehensive diagnostic evaluations, and more structured and focused treatments.
More comprehensive psychoeducation would enhance respect for the autonomous role of the
patient as well as the treatment alliance.
72
9.3 Implications for future research
More research on depression as a heterogeneous, comorbid disorder is needed. Studies on
comorbid MDD using both the dimensional and categorical models, and investigating factors
from several potentially relevant domains including genetic, biological, developmental and
environmental risk factors, should be carried out. Such studies would help us to better
understand the nature of the mechanisms underlying comorbidity, and to discover the
potential neurobiological and structural variations in MDD according to patterns of
comorbidity. Further prospective longitudinal studies are needed to search for any logical
pattern in the symptom progression, subtypes or comorbidity of MDD, over long time
periods. Ideally, child, adolesenct and adult psychiatry will collaborate in future
longitudinal research to the benefit of all.
Randomised controlled trials on both drug and psychosocial treatments should be carried
out among ordinary, highly comorbid depressive patients, including beyond the acute phase.
Ordinary psychosocial and drug treatments for MDD in various health care settings should
be investigated and compared. Information is needed to help to develop better and more
effective treatments and treatment facilities, as well as to improve co-operation between
various treatment settings. More research is also urgently needed on specific
psychotherapies.
More research needs to be conducted on the contributors to nonadherence and discontinuity
of treatments, in order to better identify patients at particular risk. Future research
should also include intervention studies and investigations of perceived interaction
between patients and treating professionals, in order to clarify these dimensions of
adherence.
Finally, studies are needed to determine whether semistructured diagnostic evaluations
improve the outcome of depression.
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